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ABSTRACT
CHARACTERIZATION OF THE BURKHOLDERIA PSEUDOMALLEI TYPE 3
SECRETION SYSTEM USING IN VIVO IMAGING
Maria Gabriela Gutierrez
November 18th, 2015

Melioidosis is a fatal infectious disease caused by the Tier 1 Select Agent
Burkholderia pseudomallei. Hallmarks of melioidosis include pneumonic disease and
prominent septicaemic spread. Both forms of disease are contingent upon the
bacterium’s intracellular life cycle and particularly on its ability to escape from host cell
phagosomes. Upon encountering a host cell, B. pseudomallei is internalized into
membrane-bound vacuoles from which the bacterium must rapidly escape to the
cytoplasm in order to replicate and promote its survival. In the host cytoplasm, B.
pseudomallei is capable of polymerizing actin for intracellular and intercellular motility
and spread, lysing the host cell and perpetuating the cycle of infection. Commonly used
intranasal and aerosol models to study respiratory melioidosis result in significant upper
respiratory tract colonization, dramatically altering disease progression. Accordingly, we
developed an improved lung-specific instillation approach to deliver bacteria directly into
mice lungs, coupled with in vivo optical imaging and observed the development of
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disease that closely resembles human melioidosis in mice. We found that in the absence
of upper respiratory tract infection, a capsular polysaccharide (CPS) mutant is only 6.8fold attenuated. This mutant is unable to spread to secondary sites of infection, consistent
with the role of capsule in protecting the bacterium from host antimicrobial activity.
Similarly, a type 3 secretion system cluster 3 (T3SS3) structural mutant is spread
deficient, yet this mutant is attenuated 290-fold, strongly suggesting that T3SS3 is critical
for respiratory melioidosis. Having a strong platform for studying the pathogenesis of B.
pseudomallei in a mouse model of lung-specific melioidosis, we used transposon
mutagenesis to comprehensively identify virulence factors required for B. pseudomallei
lung colonization and spread to the liver and spleen. Notably, T3SS3, capsular
polysaccharide and type 6 secretion system cluster 5 (T6SS5) were the major genetic loci
required for respiratory melioidosis. A T6SS5 mutant is not attenuated by LD50
estimations using our lung-specific melioidosis mouse model. Yet by competition
analysis T6SS5, T3SS3 and CPS mutants were attenuated, substantiating the requirement
of these factors for B. pseudomallei infection as previously reported. These results
highlight the importance of competition analysis for studying the fitness of distinct
virulence determinants. Importantly, T3SS3 was the only virulence determinant
attenuated by both LD50 analysis and competition studies, corroborating the critical
requirement of this virulence system for respiratory melioidosis. B. pseudomallei is a
facultative intracellular cytosolic bacterium and its ability to survive intracellularly is
fundamental to mammalian host infection. Upon B. pseudomallei internalization into
host cell vacuoles, the bacterium rapidly escapes this compartment by action of the
T3SS3. The T3SS3 is required by B. pseudomallei for intracellular survival by
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translocating protein effectors to the cytoplasm of host cells and mediating the rapid
escape of the bacterium from phagosomes of these cells. We hypothesized that effectors
act in concert to mediate B. pseudomallei’s rapid escape from phagosomes of host cells
by manipulating host signaling pathways and promoting bacterial survival. Using a highresolution, high-throughput in vivo imaging screening approach we profiled the
contributions of five of the six B. pseudomallei putative type 3 effectors to the
bacterium’s rapid phagosome escape. Effector mutants exhibited distinct temporal
differences in escape, with bopA inactivation resulting in the most pronounced delay in
vacuolar rupture, strongly suggesting that BopA directly mediates escape of B.
pseudomallei from endocytic vesicles. We confirmed that a previously identified BopA
host target, the trafficking particle protein C8 (TRAPPC8), colocalized with Burkholderia
containing vacuoles. Small interfering RNA knockdown of this protein strongly suggests
that TRAPPC8 is required for vacuolar membrane stabilization. These findings
substantiate the significant role of the T3SS3 and provide a paradigm to study B.
pseudomallei natural infection processes and potential vaccine and therapeutic targets.
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CHAPTER I

BURKHOLDERIA PSEUDOMALLEI AND MELIOIDOSIS

1.1 Identification of Burkholderia pseudomallei
Burkholderia pseudomallei, the causative agent of melioidosis, was first isolated
by the pathologist Alfred Whitmore and his assistant C. S. Krishnaswami in April 1911
during a routine post-mortem examination of a morphine addict in the Laboratory of the
Rangoon General Hospital in Rangoon, Burma [1]. Lung smears from the diseased man,
identified the bacterium as a Gram-negative, non-motile organism that resembled
Burkholderia mallei, the etiological agent of glanders, in both shape and size [1, 2].
Standard bacteriological examinations revealed that the organism isolated from the
diseased lung yielded an abundant number of bacteria in broth culture after a three-day
growth period [1, 2]. Curiously, this “rapid and luxuriant growth” in culture was unlike
that of B. mallei, and male guinea pigs infected via intraperitoneal inoculation with the
bacterium in question expired without inflammation of the testicles, a hallmark of
glanders infection in male guinea pigs [1]. Expansion of bacteria isolated from the
guinea pig bore a motile bacillus, leading Whitmore to hypothesize that the organism
isolated from both the human and guinea pig lungs was motile in early cultures but lost
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its motility within a few days [1]. The striking similarities between the human and
animal cases prompted the investigation of additional post-mortem examinations
conducted within the past few months. The bacterium was isolated in 38 separate
incidents and examinations revealed patches of lung consolidation in the majority of
victims. These patches became the hallmark of the unknown bacillus’ pathology [1].
Thereupon, Whitmore characterized the bacterium as rod-shaped, Gram-negative, non
acid-fast, displaying bipolar staining by Leishman’s stain [1]. In broth culture, the
bacillus was capable of rapid, abundant growth under aerobic and anaerobic conditions
with formation of a thin white surface layer or pellicle and a thick bacterial aggregate
undermost after extended periods of growth [1, 2]. Further, bacilli in young cultures
expressed motility of a “serpentine character,” which was later lost [1]. In agar, young
bacterial colonies appeared moist and translucent, thickening into cream-colored colonies
and shifting to wrinkled, pink-hued colonies after extended periods of growth [1, 2].
Characterization of the unknown organism led Whitmore to propose the name of Bacillus
pseudomallei for the deadly bacterium [1].
In 1913 and 1917, investigations by A.T. Stanton and William Fletcher into
several human infections and what was thought to be a distemper outbreak in mice at the
Institute for Medical Research in Kuala Lumpur, Malaysia, isolated the same bacterium
[2]. The cause of these outbreaks was again mistakenly concluded to be B. mallei, as
clinical manifestations of B. pseudomallei pathology closely resembled those seen in
glanders patients. Yet in 1917, Stanton concluded that the illness of animals and man in
Kuala Lumpur was caused by B. pseudomallei [2]. In 1921, Stanton and Fletcher wrote
an account of their experiences with the malady and proposed to rename the organism
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Bacterium whitmori in honor of Whitmore, who first isolated and characterized the
bacillus [2]. Further, the physicians proposed the name Melioidosis for the illness, for
ancient Greek physicians referred to maladies that resembled (“eidos”) distemper of asses
as “melis” [2, 3]. But since its discovery the bacterium has been reclassified into
numerous genera, Malleomyces in 1939 [4], Pseudomonas in 1957 [5] and finally
Burkholderia in 1992, when Yabuuchi et al. proposed the transfer of seven bacterial
species to the new Burkholderia genus based on 16S rRNA sequences, DNA-DNA
homology, cellular lipid and fatty acid composition and phenotypic characteristics [6].

1.2 Epidemiology
Burkholderia pseudomallei is an environmental free-living organism commonly
found in the soil and stagnant water in endemic areas [7]. Scant human cases in Burma,
Kuala Lumpur and Singapore marked the discovery of B. pseudomallei, the causative
agent of melioidosis [1, 2, 8]. Years after the initial discovery of melioidosis,
Krishnaswami and Knapp reported that B. pseudomallei had been isolated in
approximately 5% of post-mortem bacteriological examinations conducted at Rangoon
General Hospital [8]. Environmental surveys conducted in Malaysia, Singapore and
Thailand revealed B. pseudomallei’s expansive prevalence in soil and water sources in
the region [8]. In Java, Indonesia awareness of melioidosis led to an increase in case
reports in humans and wild animals [8]. Around the same time, China, Hong Kong,
Korea, the Philippines and Sri Lanka also began to report endemic cases of melioidosis
[8]. And in Vietnam, the first case of melioidosis was confirmed in 1925 [8].
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Importantly, the Vietnam War brought great notoriety to the disease in the region.
Interest in melioidosis arose in the United States and Europe, as a result of military
service men fighting in Southeast Asia becoming ill with the malady during and after the
conflict [9]. It was estimated that approximately 225,000 American service members
were exposed to B. pseudomallei during the war, based on seroconversion studies [10].
Around the same time in Thailand, increased awareness also shed light into the
prevalence of the disease in the region, with a 29.1% B. pseudomallei seroconversion rate
in healthy Thais reported in 1962 [8]. It has been estimated that one in five children
under the age of 14 fall ill to melioidosis with a 51% mortality rate [11]. Alarmingly,
current studies estimate that a large number of healthy individuals in the region have
antibodies against B. pseudomallei by the age of 4 years and that the bacterium is
responsible for up to 20% of community acquired septicaemia with an associated 50%
mortality rate in the region [3, 11-13].
In northern Australia, the mortality rate associated with melioidosis is significant
at approximately 20% [3, 10]. Striking figures from several studies showed that males
are at great occupational risk as 69% of melioidosis patients were males involved in
farming activities [10]. Approximately 39% of patients suffered from diabetes mellitus
and 81% of all infections were contracted during the wet season [10]. Diabetes mellitus
represents the highest pre-existing risk factor associated with melioidosis patients [13].
Surprisingly, the lack of pre-existing risk factors prior to infection with the bacillus was
the sole “strongly predictive of survival” [10]. To date, B. pseudomallei infection is the
“most common cause of fatal community-acquired septicaemic pneumonia in northern
Australia” [3].
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In Central and South America, sporadic cases of melioidosis have been reported
more recently in El Salvador, Panama, Ecuador and Brazil [8, 14]. In Brazil, numerous
outbreaks of melioidosis have been reported and the bacterium has been isolated from
river water and mud, strongly suggesting that B. pseudomallei may be endemic to eastern
coastal regions of the country [14]. Yet, unavailability of adequate diagnostic methods
and the lack of familiarity with the disease in Latin American countries may lead to
melioidosis being under-diagnosed in this region. In North America, the etiology of most
melioidosis cases reported can be traced back to recreational or occupational travel to
melioidosis endemic regions [14, 15]. In the United States, only five melioidosis cases
have been reported with no history of travel to endemic regions, yet multi-locus sequence
typing traced back the origins of three of these strains to Southeast Asia [16]. In addition,
a great number of melioidosis cases were reported in veterans of the Vietnam War, which
presented with acute febrile illness years after arriving back in the United States
following the armed conflict [14]. Surprisingly, the longest disease-free interval recorded
was 62 years for a veteran of the Pacific War [14]. In 2014, two cases of B. pseudomallei
infection were reported in domesticated animals imported from Central America to the
United States, thus the bacterium is also capable of persisting in animals years after initial
infection [17]. Melioidosis is believed to be under-diagnosed in Central and South
America, where incidence of the disease is mainly observed in rural and remote
communities. Accordingly, improvements of rapid diagnostic methods and increased
clinical awareness may be imperative for accurate identification, treatment and
prevention of B. pseudomallei in this region [14].
Finally, melioidosis incidence not only in Southeast Asia and northern Australia,
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but endemic pockets in the Middle East, Africa and Central and South America resolved
that B. pseudomallei is likely native to the world’s tropical and subtropical regions
located between 20° N and 20° S of the Equator (Figure 1), however the increase of
animal and plant exports from endemic regions to other parts of world, strongly suggests
that exposure of the bacterium to other parts of the world may be on the rise [3, 9, 18].

1.3 Clinical Melioidosis
Infection with B. pseudomallei is primarily acquired through percutaneous
inoculation via skin abrasions during occupational or recreational exposure to the
bacterium, inhalation of organisms in aerosolized dust or water predominantly during
heavy rain periods and ingestion [7, 10, 19]. The incubation period of melioidosis is
approximately1-21 days, with a mean incubation period of just 9 days [10]. Factors
influencing the morbidity and mortality associated with B. pseudomallei infection
include: host risk factors such as diabetes mellitus, alcoholism and renal disease,
infectious dose, route of infection and virulence associated with the infecting B.
pseudomallei strain [10]. In Australia, a vast majority (~85%) of reported melioidosis
cases were acute in nature; with symptoms lasting less than 2 months and 11% of cases
were chronic, with symptoms exceeding 2 months [10].
During infection, B. pseudomallei can be isolated from the blood, sputum, urine
and superficial lesions of patients for diagnosis of culture-confirmed melioidosis [2]. The
bacillus spreads through the blood stream very early in infection, which is supported by
the septicaemic nature of melioidosis in guinea pigs [2]. Lung infection seems to be an
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early event in the course of the disease [2], with autopsy results of fatal melioidosis cases
showing patches of pale and caseous lung consolidation as a hallmark of the disease [1, 2,
20]. Further, B. pseudomallei is capable of causing focal lesions in every organ of the
body with exception of the gastrointestinal tract and lymphatic system [9, 20]. Infection
of the liver and kidneys with presentation of small caseous and necrotic patches of
haemorrhagic zones and enlarged and softening of the spleen are also considered
hallmarks of melioidosis [1, 2]. Transmission of melioidosis from person to person is
unusual, only one case of perinatal transmission and one case of sexual transmission have
been documented [3] and infection from animals to humans have never been reported [9].
Melioidosis manifestations take a vast array of forms and diagnosis may be
impossible in early stages [2]. Accordingly, the malady has been termed “the great
mimicker” [11]. Stanton and Fletcher likened melioidosis manifestations to those seen in
malaria, enteric fever or tuberculosis, cholera, syphilis, plague, typhoid fever, mycosis,
delirium, acute rheumatism and amoebic abscesses of the liver [2, 9]. Clinical
presentations can range from asymptomatic seroconversion, acute or chronic pneumonia,
genitourinary infection, osteomyelitis, localized skin, hepatic and spleen abscesses,
neurological complications and fulminant septicaemic disease, which is the deadliest
form of the illness [11, 13]. A recent report correlated the route of B. pseudomallei
infection with presentations of bacteremia or pneumonic disease [21], finding that
percutaneous inoculation is negatively associated with bacteremia, ingestion is associated
with bacteremia and inhalation of the bacterium is associated with pneumonic disease
[21]. Although, the primary route of inoculation with the bacterium in endemic areas
occurs through percutaneous exposure, a shift to inhalational infection as the predominant
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route of inoculation may occur during the rain season, as evidenced by the increase in
incidence of melioidosis cases [16, 22, 23]. Yet, pneumonic disease remains the most
common disease presentation in studies of melioidosis patients, with up to 90% mortality
associated with septic shock from acute melioidosis pneumonia [16].
Antibiotic treatment of melioidosis is extremely limited due to the bacillus’
intrinsic resistance to many classes of antibiotics commonly used to treat bacterial
infections such as macrolides, beta-lactams, aminoglycosides and polymyxins [9, 13]. B.
pseudomallei encodes for multidrug efflux systems on chromosome 2 given that the
bacterium does not carry any plasmids [11], suggesting that antibiotic resistance
promotes the bacterium’s environmental survival and that these drug resistance
determinants have not been recently acquired nosocomialy, as is common for other
multidrug resistant pathogens.
Melioidosis treatment for culture-confirmed cases includes a lengthy biphasic
course of antibiotic therapy, divided into an acute phase and an eradication phase of
treatment [16, 24]. In the acute phase of treatment, the recommended therapy is
continuous infusion or intravenous administration of the β-lactam ceftazidime for
approximately 7-28 days with the goal of bacteremia eradication [24, 25]. Alternate
treatment of severe melioidosis patients with meropenem, showed that this antibiotic may
be more efficient for the treatment of severe melioidosis, but comparative studies
between the efficacy of ceftazidime and the latter are not available [26]. In the
eradication phase, patients are treated with oral trimethoprim-sulfamethoxazole for
approximately 12 to 20 weeks, with the goal of eradicating surviving B. pseudomallei and
avoiding recrudescence of the bacillus [24, 27]. However, relapse after apparent
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clearance of the bacillus is common. Accordingly, melioidosis was termed the “time
bomb disease” for its ability to recrudesce many years post latency, with 62 years being
the longest reported quiescence period after initial infection [8, 10]. Nevertheless,
approximately 25% of patients with intermittent melioidosis are newly infected with a
different B. pseudomallei strain rather than relapsing from initial infections [13, 24, 28].
For individuals who may be at risk of occupational exposure to B. pseudomallei,
such as laboratory workers, the recommended post exposure prophylaxis include oral
trimethoprim-sulfamethoxazole as the primary antibiotic cocktail of choice if the patient
has no documented allergies to either drug and the infectious B. pseudomallei strain is
susceptible to the antibiotics [29]. In cases of documented allergies or antibiotic
resistance, doxycycline or amoxicillin-clavulanic acid may be administered, but
doxycycline treatment alone is associated with higher relapse rates of infection and
treatment failure, and amoxicillin-clavulanic acid has been shown to be more efficient in
the treatment of naturally acquired melioidosis [29].

1.4 Burkholderia pseudomallei genetics
B. pseudomallei’s remarkable genomic plasticity facilitates its ability to inhabit
diverse niches, as horizontal gene acquisition has played a significant role in the
evolution of the pathogen’s genome [30, 31]. The bacterium’s genome is one of the
largest, genetically diverse genomes sequenced to date [11, 30, 32]. The 7.25-megabase
B. pseudomallei genome is comprised of a 4.07-megabase large chromosome,
chromosome 1, and a smaller 3.17-megabase chromosome, chromosome 2, [11] with
approximately 6,332 protein-coding sequences [32]. Sequences in chromosome 1 encode
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for proteins considered core to the B. pseudomallei genome, these are required for growth
and metabolism functions such as macromolecule metabolism, nucleotide and protein
biosynthesis, amino acid metabolism, chemotaxis and motility, among other components
with shared genetic order in other prokaryotes [31, 32]. Chromosome 2 primarily
encodes for proteins with accessory functions for adaptation and survival in different
environments such as secondary metabolism, osmotic protection, iron acquisition,
horizontally acquired DNA, hypothetical proteins and other components associated with
plasmid replication, but with little to no conserved genetic order is shared with other
prokaryotes [2, 32]. The smaller replicon also contains coding sequences critical for
growth and metabolic functions, such as tRNA genes, an rRNA gene cluster and
components of the replication and trasnscription machineries, thus chromosome 2 is
classified as a chromosome rather than a megaplasmid [11]. Approximately 80 to 86% of
the B. pseudomallei core genome distributed between both chromosomes is homologous
among more than 111 B. pseudomallei clinical, environmental and animal isolates [11,
12, 31, 32], and of the core genome, ~8% of genes are considered essential [33]. Clinical
isolates of the bacillus cluster together in phylogenetic trees based on genomic
variability, which is suggestive of differential virulence potential among different isolates
[12]. Although the B. pseudomallei large chromosome shares discrete regions of
conserved genetic order with the large chromosome of other pathogens such as R.
solanacearum, the smaller chromosome does not share conserved gene order, strongly
suggesting differential ancestry for the smaller chromosome [11].
Genomic or pathogenicity islands, which are regions of DNA likely acquired
through horizontal gene transfer, are variably found in clinical B. pseudomallei strains
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and other pathogenic bacteria and are often associated with virulence in many bacterial
pathogens [34]. The B. pseudomallei genome contains 16 genomic islands, 12 in
chromosome 1 and 4 in chromosome 2, which make up ~6.1% (~4.4 Kb) of the
bacterium’s genome, consistent with the principle that genomic or pathogenicity islands
occupy large genomic regions in pathogenic bacteria [11, 34]. B. pseudomallei’s fitness
in diverse niches is reasoned to be directly mediated by the bacterium’s genetic plasticity
and diversity supplemented in part by genomic islands [12, 32] and the presence of these
genomic islands in B. pseudomallei clinical isolates suggest that these regions may play
key roles in the bacterium’s virulence by predisposing these strains to cause disease in
humans [12].

1.5 Burkholderia pseudomallei intracellular life cycle
Following internalization into target cells B. pseudomallei is contained within
membrane-bound vacuoles, followed by bacterial escape into the cytoplasm [35].
Following escape of the bacterium from endocytic vesicles, B. pseudomallei is free to
replicate in the cytoplasm of host cells, polymerizing actin at one pole resulting in
intracellular motility and intercellular spread, eventually lysing the host cell (Figure 2).
Vacuoles containing B. pseudomallei T3SS3 mutants incapable of vacuolar escape
colocalize with the lysosome marker LAMP-1 and with the autophagy marker LC3 [36].
However, T3SS3 mutant-containing vacuoles do not possess the double membrane
characteristic of autophagosomes, suggesting that B. pseudomallei infection does not
trigger autophagy in host cells [36]. Alternatively, it has been proposed that LC3 may be
recruited to T3SS3 mutant-containing vacuoles through LC3-associated phagocytosis,
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resulting in decreased bacterial survival [37]. Accordingly, vacuolar escape is critical for
the bacterium’s intracellular lifestyle, thus this process must occur rapidly following
internalization. The precise time B. pseudomallei escapes from vacuoles remains
unknown, yet the kinetics of vacuolar escape of other cytosolic pathogens such as
Francisella tularensis, Shigella flexneri, Listeria monocytogenes and Rickettsia spp.
range from 15 to 60 minutes post internalization, suggesting that B. pseudomallei escapes
phagosomal vesicles in a comparable time frame [35]. Vacuolar escape of cytosolic
pathogens is a bacterial-driven process and for B. pseudomallei the T3SS3 mediates this
event (discussed in section 1.6.3) [38].

1.6 Burkholderia pseudomallei virulence determinants
Characteristics of melioidosis such as difficulty in treating infection and instances
of prolonged quiescent periods after initial infection followed by relapse years later,
suggest that B. pseudomallei is a facultative intracellular pathogen [39-41]. Further, the
bacterium is capable of surviving and replicating within human polymorphonuclear
leukocytes, monocytes and phagocytic and non-phagocytic cultured cells [39-41]. B.
pseudomallei and other pathogenic bacteria possess the ability to cause disease in humans
through the use of virulence factors that allow the bacteria to successfully overcome host
immune mechanisms. Key B. pseudomallei virulence factors include the capsular
polysaccharide (CPS), type 6 secretion system (T6SS), type 3 secretion system (T3SS),
quorum sensing, lipopolysaccharide, flagellin, type 2 secretion system, type 4 pili and
phospholipase C among other undescribed factors [7]. These virulence systems are
required for different aspects of B. pseudomallei host intracellular, extracellular and
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environmental survival, herein we concentrate on T3SS3, CPS and T6SS5, which are the
focus of our studies.

1.6.1 Type 3 Secretion Systems
The type 3 secretion system is a needle-like apparatus that translocates effector
proteins across both Gram-negative bacterial membranes into the cytoplasm of eukaryotic
cells [42, 43]. The Gram-negative type 3 machinery is made up of ~15-20 scaffolding or
structural proteins that make up the basal body that spans both bacterial membranes, and
the secretion apparatus or needle that delivers effectors to its host target [7, 42, 44]. In its
genome, B. pseudomallei encodes 3 type 3 secretion loci [38, 45, 46]. Clusters 1 and 2
share homology with the plant pathogens Ralstonia solanacearum and Xanthomonas spp.
[45] T3SS and cluster 3 (T3SS3) shares homology with the Salmonella typhimurium
Inv/Spa/Prg and the Shigella flexneri Ipa/Mxi/Spa type 3 secretion systems, required for
intracellular survival of both pathogens [46].
The T3SS is critical for the intracellular life cycle and survival of pathogenic
bacteria such as Shigella spp., Salmonella spp., E. coli, Yersinia spp. and Pseudomonas
aeruginosa [43]. The intracellular life cycle of B. pseudomallei and other pathogenic
cytosolic bacteria such as Shigella flexneri consists of escape from host cell vacuoles
following internalization, replication in the cytoplasm of the host cell (Figure 2) and
manipulation of host cell signaling pathways that promote the bacterium’s intracellular
fitness [35]. B. pseudomallei has evolved to rapidly escape from endocytic vacuoles
through the use of the type 3 secretion system cluster 3 [35]. Upon contact with the
vacuolar membrane, the B. pseudomallei type 3 secretion apparatus forms a channel
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between bacteria and host, secreted translocon proteins and the needle tip form a pore in
the vacuolar membrane translocating very small amounts of effector proteins into the
cytoplasm of the target cell [42, 44, 47]. B. pseudomallei injects type 3 secretion
effectors across vacuolar membranes following internalization to rapidly escape to the
cytoplasm, where the bacteria can continue its life cycle, bypassing killing by the host
cell and eventually lysing the cell [39]. Translocated effectors may interact with host cell
proteins facilitating the rapid escape of B. pseudomallei from endocytic vesicles by
manipulating signal transduction pathways in the cell, promoting bacterial survival and
spread [43]. Major hallmarks of type 3 secretion effector functions in other bacterial
pathogens include inhibition of phagocytosis, cytoskeletal rearrangement, mediation of
escape of the bacterium from host vacuoles, manipulation of cellular signaling pathways
that promote bacterial survival, down-regulation of host cell inflammatory response or
inhibition of apoptosis [43].
The B. pseudomallei T3SS3 is the only type 3 secretion system of critical
importance for B. pseudomallei virulence in mammals, as it is the only cluster required
for virulence in a Syrian golden hamster model of systemic melioidosis [7, 19].
Conserved type 3 secretion apparatus components were named Sct by Attree and Attree,
but were later designated bsa (Burkholderia secretion apparatus) by Stevens et al.,
leading to multiple nomenclatures for T3SS3 [38, 46]. A mutant in a component of the
T3SS3 export apparatus, sctU, exhibits no effector secretion and almost no intracellular
replication in cultured macrophages when compared to wild type strains, strongly
suggesting that T3SS3 is critical for intracellular fitness of B. pseudomallei [38, 48].
This mutant remains trapped in endocytic vesicles of cultured macrophages up to 12
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hours post infection, although early in infection ~95.1% of bacteria were associated with
the lysosomal marker lysosome-associated membrane glycoprotein-1 (LAMP-1) [38].
Actin tail formation, a hallmark of Shigella spp., Rickettsia spp. and L. monocytogenes in
the cytoplasm of host cells, is also impaired in this mutant, again supporting the
previously observed escape deficient phenotype of the sctU mutant [38]. These data
demonstrate that the B. pseudomallei T3SS3 is critical for intracellular survival of the
bacterium by mediating the bacterium’s rapid escape to the cytoplasm of host cell.
Translocation of T3SS3 effectors is mediated by a set of translocon proteins and
the T3SS3 apparatus needle tip termed Burkholderia invasion proteins (Bips), which
form a pore in the vacuolar membrane of the host cell and include BipB, BipC and BipD
[19, 38]. The Bip proteins, BipB, BipC and BipD, make up the translocon proteins and
needle tip, respectively, of the T3SS3 apparatus [44]. BipB and BipC form a pore in the
eukaryotic host cell membrane, but are also secreted into the cytoplasm; therefore it is
possible that these translocon proteins may have additional roles during B. pseudomallei
infection [44]. Accordingly, bipB and bipC mutants exhibit impaired invasion of nonphagocytic cultured cells and reduced intracellular fitness, strongly suggesting that
efficient interaction of B. pseudomallei with host cells and efficient delivery of T3SS3
effectors to the cytoplasm of the cell is required for full virulence of the bacterium [49,
50]. Notably, inactivation of bipC also leads to delayed escape of B. pseudomallei from
endocytic vacuoles, leading to a 2-fold reduction in intracellular burden in cultured cells
[50]. It is possible that inactivation of bipB leads to a similar phenotype, given that
defective formation of a translocon pore likely leads to inefficient effector delivery,
compromising the fitness of the bacterium in host cells. In addition, BipB may also have
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a role in B. pseudomallei late infection, as it has been shown to be required for efficient
cell-to-cell spread of the bacterium by promoting fusion of the plasma membrane of cells
infected with B. pseudomallei and that of neighboring cells [49]. These data suggests that
other effectors may also be required for optimal cell-to-cell spread by host membrane
fusion events and that effectors function during early and late events in the infection
process, yet cell-to-cell spread by membrane fusion has only been observed during B.
pseudomallei in vitro infection of cultured cells, so whether cell-to-cell spread by fusion
events take place in vivo remains unknown [49]. Lastly, both bipB and bipC mutants are
significantly attenuated in an intranasal BALB/c model of respiratory melioidosis,
validating the requirement for formation of a translocon pore for full B. pseudomallei
virulence in mammals [49, 50]. Thus taken together, these data suggest that efficient
formation of a translocon pore by B. pseudomallei T3SS3 translocon proteins is required
for adherence, invasion, translocation of effectors and overall fitness of B. pseudomallei
in mammalian infection.
BipD the tip of the T3SS3 needle is also required for the efficient and timely
delivery of effector proteins, stalling secretion in the absence of host cell contact [44].
Consequently, inactivation of bipD renders the bacterium incapable of efficient escape
from endocytic vesicles, impaired intracellular replication and decreased intracellular
survival in cultured macrophages, consistent with the phenotypes observed for bipB and
bipC mutants, which make up the translocon pore [50, 51]. Crystal structures of BipD
and its Shigella homologue IpaD, suggest that BipD may play a role as an extracellular
chaperone, by guiding and mediating the insertion of BipB and BipC into the host cell
membrane and by potentially tethering the translocon pore to the T3SS needle [51].
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Notably, the crystal structure of BipD shows that the protein contains a highly conserved
region at its C-terminal end that may be involved in protein-protein interactions with the
translocon pore [51, 52]. Importantly, purified BipD, as well as BipB and BipC, strongly
react with serum from convalescent melioidosis patients and other T3SS3 components
have been successfully used in experimental vaccines in animal models, strongly
suggesting that these proteins may constitute potential therapeutic and vaccine candidates
[38]. Yet, vaccination of BALB/c mice with purified BipB, BipC or BipD did not confer
immune protection against intraperitoneal challenge with wild type B. pseudomallei
protein, suggesting that these proteins may be secreted in very low amounts or that host
antibodies may not have access to these proteins as B. pseudomallei is a facultative
intracellular pathogen [53].
B. pseudomallei effector proteins were named Burkholderia outer proteins or
Bops and constitute BopA, BopC and BopE, named in a similar manner to Salmonella’s
outer proteins [19, 38]. The Burkholderia secretion apparatus (Bsa) associated proteins
or Baps (BapA, BapB and BapC), have no known function as of yet in type 3 secretion
[19, 38], although recent studies confirmed that BapA [54, 55] and BapC [55] are
secreted in vitro in a T3SS3-dependent manner, suggesting that the Bap proteins may
contribute to the intracellular survival of the bacterium in host cells. Bop and Bap T3SS3
effector proteins are translocated into the cytoplasm of host cells by the T3SS3 apparatus
during infection [19, 38].
The Burkholderia outer proteins, BopA, BopC, BopE, BapA and BapB are the B.
pseudomallei T3SS3 putative translocated effectors, which most likely contribute to
replication, survival, spread and ultimately persistence of the bacterium within its host.

17

BopA is critical for the rapid escape of B. pseudomallei from endocytic vacuoles of
cultured macrophages, as bopA mutants exhibit delayed escape from RAW264.7
phagosomes, demonstrating that BopA directly mediates vacuolar rupture in cultured
phagocytic cells [36]. In addition, the vacuole containing this mutant co-localizes with
the autophagy marker microtubule-associated protein light chain-3 (LC3) and the
lysosome marker LAMP-1 for longer periods of time than the wild type vacuole, leading
to increased killing by LC3-associated phagocytosis and subsequent decreased
intracellular replication in cultured macrophages [36]. Yet the bopA mutant does not
trigger cellular autophagy, rather reduced intracellular bacterial numbers during infection
are a result of delayed escape of the mutant into the cytoplasm, confirmed by electron
transmission microscopy [36]. In addition, the bopA mutant is capable of inducing actin
tail formation at later times during infection, supporting the previously observed delayed
escape phenotype [36]. Further studies are needed to demonstrate the mechanism by
which BopA mediates vacuolar escape and other potential contributions of this effector to
the intracellular life cycle of the bacterium.
BopE is also secreted in a T3SS3-dependent manner in vitro [48]. Consistent
with phenotypes observed with inactivation of its Salmonella-homologues SopE and
SopE2, which promote bacterial invasion of non-phagocytic cells, inactivation of bopE is
associated with significant reduction in invasion of HeLa cells [48]. Yet, B. pseudomallei
is only weakly invasive when compared to Salmonella and is phagocytosed into cells
rather than promoting its own uptake [39]. BopE is an effective guanine nucleotide
exchange factor (GEF) for the SopE and SopE2 mammalian target proteins Cdc42 and
Rac1, but with a lower exchange rate, suggesting that BopE may target other host
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GTPases and may be required for effector functions other than invasion of host cells [48].
Notably, the invasion rate of B. pseudomallei in numerous epithelial and fibroblast cell
lines is low compared to invasive Salmonella, again suggesting that Cdc42 and Rac1,
which are involved in cytoskeleton rearrangement, are not targeted by B. pseudomallei
for invasion. In a similar manner, BopC in vitro secretion is dependent on a functional
T3SS3 apparatus and inactivation of this effector is also associated with reduced invasion
of the human A549 epithelial cell line [56]. But, very little data is available on the
functions of BopE and BopC during infection, thus further studies to discern the
contributions of these effectors to the B. pseudomallei intracellular life cycle are of
pressing concern, as no role has been attributed to either effector during infection of host
cells. Overall, these data strongly suggest that a functional B. pseudomallei T3SS3 and
efficient delivery of T3SS3 protein effectors is critical for the pathogenesis of the
bacterium in host cells. Specifically, T3SS3 is critically required for efficient adherence,
invasion, rapid vacuolar escape and intracellular fitness, promoting and mediating the
survival of B. pseudomallei in mammalian hosts. Importantly, translocation of effectors
and interaction of these effectors with host proteins, as evidenced by S. flexneri and S.
enterica T3SS3 effectors, promotes intracellular fitness of B. pseudomallei. Accordingly,
extensive studies are needed to elucidate the individual contributions of type 3 effectors
to the intracellular life cycle of B. pseudomallei in efforts to find potential vaccine targets
or therapeutics against B. pseudomallei infection.
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1.6.2 Capsular Polysaccharide
The capsular polysaccharide makes up the outermost layer of Gram-negative bacterial
cells. It is composed of highly hydrated homo- or heteropolymers of repeating
monosaccharides joined together by glycosidic bonds in distinct numbers of
configurations, resulting in highly diverse capsular structures synthesized by different
bacterial species [57]. Capsule production has been associated with virulence in bacteria
that cause serious human diseases, given that capsule mediates interactions between
bacterial cells and their environment [58]. As a result, the capsular polysaccharide is
characterized as a key virulence determinant for many pathogenic bacteria [57].
Importantly, the bacterial capsule has been implicated in protecting the bacterial cell
against desiccation, promoting transmission and survival, adherence to target cells,
resistance to opsonophagocytosis and protection against complement-mediated lysis and
host specific immunity [59, 60].
The B. pseudomallei genome contains 4 operons (CPS I-IV) with genes predicted
to be required for biosynthesis and export of 4 different capsular polysaccharides [58].
CPS I encodes a capsular polysaccharide similar to that produced by the human
pathogens Escherichia coli, Haemophilus influenzae and Nisseria meningitidis [59, 61].
Genes with predicted biosynthetic functions in this operon share homology to genes
required for synthesis of structures primarily composed of mannose, and genes with
predicted functions in polysaccharide export share homology to those found in various
bacterial species that serve the same function [58]. G+C content of this operon is ~58%,
substantially lower than the 68% G+C content in the rest of the genome, suggesting
potential acquisition of this operon through horizontal gene transfer [58]. The CPS I
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operon is also found in B. mallei, a host adapted clone of B. pseudomallei that is
pathogenic to mammals [58]. In contrast, CPS II, CPS III and CPS IV are also found in
the B. pseudomallei avirulent relative Burkholderia thailandensis but not in B. mallei
[58]. Accordingly, the CPS II, III and IV loci do not contribute to the virulence of B.
pseudomallei in mammals, strongly suggesting that these loci may be required for
environmental fitness of the bacterium [58].
To date, the B. pseudomallei the CPS I operon is one of the most important
virulence determinants required for the bacterium to cause systemic melioidosis [59],
given that capsule protects B. pseudomallei against specific and non-specific host
immunity [58]. Capsular polysaccharide glycosyltransferase and mannosyltransferase
genes are both required for production of major surface polysaccharides [61] and mutants
in both genes exhibit up to 10,000-fold attenuation in an intraperitoneal hamster model of
systemic melioidosis and a mouse model of acute melioidosis, respectively, corroborating
the importance of capsule for B. pseudomallei virulence [59, 62]. Further, capsule is
required for B. pseudomallei persistence in the blood by reducing complement factor C3b
deposition on the bacterial surface and by protecting the bacterium from phagocytosis by
polymorphonuclear leukocytes, which is consistent with the role of the capsular
polysaccharide in E. coli [59, 63]. Glycosyltransferase mutants are incapable of
colonizing the lung, liver and spleen of hamsters in a systemic model of melioidosis,
highlighting the importance of the capsule for establishing systemic disease [59]. In a
similar manner, the mutant strain JW270, which is missing the entire capsular
polysaccharide operon, is attenuated ~2 log in an intranasal mouse model of acute
melioidosis and is incapable of colonizing the blood at similar levels than the isogenic
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parental strain, consistent with the requirement of capsule for B. pseudomallei persistence
in the blood previously observed [60]. Yet, this mutant is capable of colonizing the lung
and liver at similar levels to that of the parental strain, and the spleen at lower levels
during lethal challenge, yet tissue damage to the liver and spleen is less severe than that
of the isogenic parental strain, suggestive of an altered host immune response against
acapsular bacteria [60]. These results also suggest that the B. pseudomallei capsular
polysaccharide may not play the same critical role for the bacterium for pneumonic
disease relative to its critical role for systemic disease.
In vitro, acapsular JW270 is internalized and capable of intracellular replication
and survival within cultured macrophages up to 9 hours post infection at levels similar to
those of the isogenic parental strain [60]. These results strongly suggest that the B.
pseudomallei capsule is not antiphagocytic for macrophages in the absence of
opsonization [60]. Bioluminescent detection of an isogenic acapsular light producing
strain in infected macrophages showed a reduction in bacterial burdens of this mutant
when compared to the parental strain at late stages of macrophage infection (>9 hours
post infection), strongly suggesting that capsule is dispensable for early stages of
macrophage infection [64]. Overall, these results highlight the importance of capsule as a
virulence determinant for systemic fitness of B. pseudomallei in mammalian hosts and
that genes required for capsular polysaccharide biosynthesis may be considered potential
therapeutic and vaccine targets for systemic disease.

1.6.3 Type 6 Secretion Systems
Type 6 secretion systems (T6SS) are bacterial virulence-associated injectisomes
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that translocate effector proteins into target eukaryotic or prokaryotic cells [65]. T6SS
are found in the genomes of ~25% of all sequenced Gram-negative bacteria and have
been implicated in cell-to-cell contact killing during host cell invasion and during interbacterial community competition [65-67]. The T6SS is comprised of ~15-20 open
reading frames encoding various apparatus components that are structurally homologous
to the components of the bacteriophage tail [68]. The apparatus is comprised of a base
plate complex that spans the inner and outer bacterial membranes and a bacteriophage
tail-like injectisome, it is highly dynamic and is hypothesized that it may be driven by a
phage tail-like contraction mechanism [65, 68]. Assembly of the base complex initiates
the polymerization of the injectisome inner tube protein Hcp and the outer phage tail-like
sheath made up of the ClpV-interacting proteins A and B (VipA and VipB) in an
extended conformation [65]. An unknown stimulus causes the contraction of the
VipA/VipB sheath leading to translocation of effector proteins to neighboring cell targets
and secretion of the tail spike protein VgrG and Hcp tubule [65]. Activity of the AAA+
ATPase ClpV is critical for disassembly of the contracted sheath in the cytoplasm of the
bacterial cell and apparatus components are recycled for use in de novo machinery
assembly [67].
The B. pseudomallei genome encodes for six evolutionary distinct T6SS
comprising ~2.3% of the bacterium’s genome, strongly suggesting that these systems
play key roles in the fitness of B. pseudomallei in diverse environments [66, 69]. Type 6
secretion phylogenetic trees show that the only B. pseudomallei type 6 locus that clusters
with eukaryotic cell targeting systems, such as those found in Vibrio cholerae and
Aeromonas hydrophila, is cluster 5 (T6SS5) and that the remaining loci cluster with
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bacterial cell targeting systems such as those found in Pseudomonas aeruginosa [66].
Importantly, T6SS5 is the only locus demonstrated to have a critical role during
mammalian virulence [66].
Secretion of the T6SS inner tube needle protein Hcp is a hallmark of a functional
type 6 secretion system [70]. Importantly, recombinant Hcp5 but not Hpc1, -2, -3, -4 or 6, strongly react with sera from melioidosis patients, suggesting that only T6SS5 is
expressed during B. pseudomallei human infection and that this protein is highly
immunogenic [70]. Expression of the B. pseudomallei VirAG two-component regulon in
trans results in transcriptional activation of T6SS5 and secretion of Hcp5 in RAW264.7
macrophages [70]. The T6SS5 genes tssM, tssI and tssH are expressed in B.
pseudomallei during growth in macrophages, demonstrating that cluster 5 encodes a
functional type 6 secretion apparatus expressed in vivo [69]. In addition, an hcp5 mutant
is ~1000-fold attenuated in a Syrian hamster model of systemic melioidosis, but not hcp1,
-2, -3, -4 or -6 mutants, again demonstrating that T6SS5 is a major virulence determinant
for B. pseudomallei for systemic melioidosis and that the other T6SS clusters may be
required for bacterial survival in environmental niches. Vaccination of BALB/c mice
with recombinant Hcp1, -2, -3, -4, -5 or -6 showed that the recombinant proteins elicit
specific antibody responses in mice, but the immune responses elicited were not
protective, suggesting that individual proteins alone may not constitute strong vaccine
candidates, but may be targeted for diagnostic testing of B. pseudomallei infection [70].
In RAW264.7 cultured macrophages, an hcp5 mutant exhibits a significant intracellular
fitness defect and reduced cytotoxicity [70]. This result contrasts with previous
observations, which showed that a mutant in the tssH-5 gene, a homolog of the AAA+
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ATPase ClpV is as fit as a wild type strain in the same cell line, yet it is possible that if
intracellular bacterial burdens would have been quantified at more than two time points,
then the intracellular fitness defect of the mutant would have been noticeable [69].
A mutant in the tag-AB gene, encoding a hypothetical protein located in the T6SS5 locus,
is highly attenuated in an intranasal BALB/c model of respiratory melioidosis [71]. And
in vitro a tag-AB mutant exhibits an intracellular fitness defect in both RAW264.7 cells
and the human lung epithelial cell line A549 [71]. Importantly, inactivation of tag-AB
leads to a pronounced defect in Hcp5 export, strongly suggesting that tag-AB is critical
for expression of functional T6SS5 machinery. Thus, taken together, these results
highlight the importance of T6SS5 to the intracellular lifestyle of B. pseudomallei, yet
very little is known about the functions of this virulence system inside host cells.
Significantly, these data demonstrate that T6SS5 is a key virulence determinant for
systemic melioidosis and that genes in these loci may serve as potential vaccine and
therapeutic targets for melioidosis in humans.
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Figure 1. Worldwide distribution of Burkholderia pseudomallei endemicity. B.
pseudomallei is highly endemic to regions of Southeast Asia and Northern Australia.
Endemic pockets of melioidosis are also found in Africa and South America. Regions
where endemicity of the bacterium is definite, probable and possible are highlighted.
Current reports indicate that the bacterium may inhabit tropical and subtropical regions
worldwide located between 20° N and 20 °S of the Equator.
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Figure 2. The Burkholderia pseudomallei intracellular life cycle. B. pseudomallei
(Bp) is internalized into a membrane-bound vacuole during host cell entry (1). Inside the
vacuole, the bacterium translocates effector proteins via the T3SS3 to disrupt the
vacuolar membrane and rapidly escape into the cytoplasm (2a) or risk getting killed by
the host cell through vacuole acidification (3b and 4b). Once free in the cytosol, bacteria
can replicate (3a) and polymerize actin for intracellular mobility and intercellular spread
(4a). These events lead to lysis of the host cell by B. pseudomallei (5a) and
dissemination of the bacterium to other sites of infection (6a).
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1.7 Specific Aims
The goal of this dissertation is to define the role(s) of the Burkholderia pseudomallei type
3 secretion system cluster 3 (T3SS3) in mediating respiratory disease. Type 3 secretion
systems are significant contributors to the pathogenesis of numerous Gram-negative
bacterial species, which utilize this injectisome to subvert host cellular defense
mechanisms by translocating effector proteins into the cytoplasm of host cells. The B.
pseudomallei T3SS3 is an important virulence determinant in both respiratory and
systemic models of disease. The T3SS3 system potentially mediates bacterial escape
from endocytic vesicles of phagocytes by employing its translocated effector proteins.
However, the overall mechanisms by which B. pseudomallei T3SS3 effectors mediate
vacuolar escape have not been elucidated. The results of this research project will further
our understanding of the pathogenesis of Gram-negative bacteria, particularly on how
T3SS and its effectors act either alone or in concert to modulate host cellular processes to
the pathogen’s benefit and importantly may provide vaccine and/or therapeutic targets
against B. pseudomallei infection. Accordingly, we hypothesize that the B. pseudomallei
T3SS3 is one of the most critical virulence determinants in a lung-specific mouse model
of respiratory melioidosis and that is also critically required for the bacterium’s
intracellular life cycle. Herein, we propose 3 Specific Aims to test this hypothesis.

Aim 1. Develop a lung-specific mouse model of respiratory melioidosis. Hypothesis:
Lung-specific delivery of B. pseudomallei would provide a more human-like model of
respiratory melioidosis.
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A. Compare in vivo disease kinetics of mice inoculated via the intranasal route or via
intubation-mediated intratracheal (IMIT) instillation.
B. Determine the course of disease of capsule and T3SS3 mutants in an IMIT mouse
model of melioidosis.

Aim 2. Identify Burkholderia pseudomallei virulence determinants required for
respiratory melioidosis and spread to secondary sites of infection. Hypothesis: A
human-like model of respiratory melioidosis would identify novel and characterized
virulence determinants required by B. pseudomallei to cause respiratory melioidosis and
subsequent dissemination to the liver and spleen.
A. Create a transposon insertion library in the genome of B. pseudomallei.
B. Validate the role of virulence determinants identified by the Tn-Seq screen in the
pathogenesis of B. pseudomallei.

Aim 3. Define the contributions of T3SS3 effectors to the intracellular life cycle of
Burkholderia pseudomallei. Hypothesis: T3SS3 effectors mediate B. pseudomallei‘s
rapid escape from host cell phagosomes by potentially modulating host signal
transduction pathways.
A. Assess the kinetics of growth of wild type B. pseudomallei, a T3SS3 structural
mutant and effector mutants.
B. Assess the individual contribution of a specific effector in mediating rapid
escape of B. pseudomallei from host cell phagosomes.
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CHAPTER II

MATERIAL AND METHODS

2.1 Bacterial strains and culture
Burkholderia pseudomallei and Escherichia coli strains were routinely cultured in
Lennox Broth (LB) at 37°C. In preparation for infection studies, B. pseudomallei strains
were subcultured 1:25 from overnight LB cultures into dialyzed and chelated Trypticase
Soy Broth (TSBDC) [72] supplemented with 50 µM monosodium glutamate and grown
for 3 hr at 37°C with shaking. When appropriate, antibiotics were used at the following
concentrations: kanamycin (Km), 25 µg/ml; polymyxin B (Pm), 50 µg/ml; streptomycin
(Sm), 100 µg/ml; and gentamicin (Gm), 20 µg/ml.

2.2 Luminescent Burkholderia pseudomallei
Luminescent B. pseudomallei strains JW280 and JW280 Δwcb were generated and
described elsewhere [73]. JW280 ΔsctUBp3 was generated by allelic exchange by using
the S17-1/pKAS46-araPtolClux construct [73] to add the luxCDABE operon to DD503
ΔsctUBp3 [19], as previously described.
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2.3 Ethics Statement
All animal studies were conducted under Biosafety Level 3 conditions using eight to ten
week old female albino C57BL/6J mice (B6 (Cg)-Tyrc-2J/J, Jackson Laboratories) bred at
the University of Louisville (Protocol Number 11113). These studies were approved by
the University of Louisville’s Institutional Animal Care and Use Committee (Protocol
numbers 10073 and 13053), in agreement with National Institutes of Health guidelines
and the “Guide for the Care and Use of Laboratory Animals” (NRC).

2.4 Mouse respiratory infections
Animal studies were conducted under Biosafety Level 3 conditions using eight to tenweek-old female or male albino C57BL/6J mice (B6(Cg)-Tyrc-2J/J, Jackson Laboratories
and in-house breeding). Freshly grown bacteria were washed into phosphate buffered
saline (PBS) to appropriate concentrations for infection using OD600-based calculations.
Intranasal infections were carried out as previously described using 30 µl B. pseudomallei
suspensions [60]. Intubation-mediated intratracheal (IMIT) instillation was performed, as
previously described, to facilitate non-surgical lung-specific disease [74, 75]. Briefly,
mice were isoflurane-anesthetized and 2% lidocaine was applied to the back of the mouth
as a local anesthetic. Mice were intubated using a 20-gauge catheter, and catheter
placement was confirmed by flow meter. Bacterial suspensions were directly instilled
into the lung using a 22-gauge blunt needle inserted through the catheter. Optical
diagnostic imaging was conducted with an IVIS Spectrum (Caliper Life Sciences) as
described previously [73, 76], with once to twice-daily imaging through day 5, and once
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daily thereafter until the study completion at day 14. Animals were euthanized at the
onset of moribund disease, which was defined by loss of righting reflex.

2.5 Bacterial enumeration at key sites of infection
Infected animals were euthanized and necropsied to enumerate bacteria from infected
tissues. Blood samples were collected by cardiac puncture, while bronchoalveolar lavage
(BAL) was collected in 1 ml of PBS. Necropsied tissues were subjected to
bioluminescence imaging (IVIS Spectrum) in a 24-well black plate before serial dilution
enumeration of bacterial burden from tissue homogenate, as described elsewhere [76].
We have defined correlations between tissue counts per second (cps) and colony forming
units (CFU) specifically for each tissue as follows: Lung, log(cps) = 1.219log(CFU) –
2.999 (R2 = 0.68); Liver, log(cps) = 1.238log(CFU) – 3.502 (R2 = 0.99); Spleen, log(cps)
= 1.088log(CFU) – 1.741 (R2 = 0.98).

2.6 Tn-Seq Library Preparation
Plasmids used in this study are identified in Table 1. To construct the transposon
delivery vector pSAM-DKm, the mariner-family transposon, Himar1 C9 transposase and
its upstream regulatory region were PCR amplified from pBTK30 and cloned as a BamHI
restriction fragment into pSAM-Bt to yield pSAM-DYH The kanamycin resistance
cassette from pEXKm5 was PCR amplified and inserted into the MfeI and XbaI
restriction sites in place of the erythromycin resistance cassette and the resulting plasmid,
pSAM-DKm was verified by PCR. To generate the B. pseudomallei Tn-Seq library, the
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E. coli S17-1 strain transformed with pSAM-DKm was conjugated with the luminescent
B. pseudomallei parent strain JW280 for 2 hrs at 37°C. Transposon mutants were
selected for on PmKm LB agar plates and grown at 37°C for 24 hrs. A library of 2x104
unique mutants were pooled, grown in PmKm LB broth with shaking at 37oC and
cryopreserved.

2.7 Tn-Seq Screen
A B. pseudomallei Tn-Seq library TSBDC culture was washed into phosphate buffered
saline (PBS) and OD600 readings were used to estimate bacterial concentrations in order
to prepare an inoculum of 104.74 CFU/50 µl. A group of three mice were inoculated with
50 µl of bacterial suspension of the Tn-seq library by intubation mediated intratracheal
(IMIT) instillation, as described [77]. Disease progression was monitored twice daily by
optical diagnostic imaging of bioluminescent B. pseudomallei until study completion, as
described [78]. Animals were euthanized at moribund endpoints (66 hrs post infection)
and necropsied to collect lungs, liver and spleen. Tissues were homogenized and bacteria
from these tissues were cultured in LB broth overnight at 37°C with shaking.
Bioluminescence imaging data was processed as described [77].
Chromosomal DNA was purified from triplicate biological samples [79] and pooled for
each tissue. Genomic DNA was digested with the MmeI restriction enzyme overnight at
37°C, treated for 20 minutes at 80°C to inactivate the enzyme, purified using the
QIAquick, PCR purification kit (Qiagen) according to the manufacturer’s instructions,
and concentrated with a speed vacuum to a final volume of 30 µl. Restricted fragments
were separated by electrophoresis in a 1% agarose gel and fragments corresponding to
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1.2 to 1.5 Kb were isolated using the QIAquick Gel Extraction Kit (Qiagen). Fragments
were ligated to barcoded double stranded adaptors using T4 DNA ligase in 50 µl
reactions overnight at 16°C, treated at 65°C for 10 minutes to inactivate the ligase, and
purified using the QIAquick PCR purification kit. Transposon-genome junctions were
amplified by PCR using the LIB_PCR_5 (5′CAAGCAGAAGACGGCATACGAAGACCGGGGACTTATCATCCAACC TGT-3′)
and LIB_PCR_3 (5′-AATGATACGGCGACCACCGAACACTCTTTCCCTACAC
GACGCTCTTCCGATCT-3′) primers [80] using HiFi DNA Polymerase (KAPA
Biosystems). Confirmation of a 125-bp product was conducted using 1% agarose gel
electrophoresis, and libraries were sequenced using Illumina 50-bp single end sequencing
at the Harvard Medical School Biopolymer Facility. Data was analyzed by sorting based
on barcodes using a custom script in Java Eclipse, then using CLC Genomics Workbench
v. 7.2 for subsequent bioinformatics. Reads were trimmed to remove adapter and
transposon sequences and aligned to the B. pseudomallei 1026b genome using the default
settings in the RNA-seq function in CLC. Reads that mapped to multiple locations were
discarded. The resultant reads were counted and normalized to the reads per kilobase of
transcript per million reads mapped (RPKM) and compared across sample sites.
Significance was assessed using the On Proportions function of CLC using the Kals’s test
option and the Bonferroni multiple testing correction was applied to the comparisons.
Initially, fold change measurements of less than -3 (reduced in the mouse samples
compared to the input pool) with a Bonferroni-adjusted p-value of less than 0.05 were
considered significant.
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2.8 Early Dissemination Studies
Early dissemination studies were conducted using the B. pseudomallei Tn-Seq library
strain to infect groups of three animals by IMIT as described above, euthanizing groups
at 6, 12 and 24 hrs post infection. Lung, liver and spleen from individual animals were
collected at necropsy, homogenized and serial diluted for bacterial enumeration as
described [77].

2.9 Type 6 Secretion System Mutagenesis
To generate a Type 6 Secretion System cluster 5 (T6SS5) mutant in B. pseudomallei, an
internal in-frame 1,437 bp region of the tssC-5 gene was deleted. Briefly, flanking
fragments in the 5’ and 3’ region of the tssC-5 gene were amplified with the following
primer sets: 5-tssC-F, GAAGAATTCGCGTAGAACAGCAGCAGCAGCAGCCCCGC;
5-tssC-R, GTCAAGCTTCGGGGATTGCAGGTGTTCGCCTTCCATGGTC; 3-tssC-F,
GTCAAGCTTTCGCTCGTCGGCAAGCTCGAAAAGCGCTAGG; 3-tssC-R,
GGCGGTACCTTGCGCGAAGCCGCCCGCGAG. The amplified 5’ tssC-5 fragment
was cloned into pSK as an EcoRI/HindIII fragment to yield pSK-5’tssC. The amplified
3’ tssC-5 fragment was cloned into pSK-5’tssC as a HindIII/KpnI fragment to yield pSKΔtssC-5. The assembled fragment was cloned into pKAS46 as an EcoRI/KpnI fragment
to yield pKAS46-ΔtssC-5 and conjugated with the parent B. pseudomallei strain DD503.
Finally, the bioluminescent strain JW280 ΔtssC-5 was constructed by conjugation of
DD503 ΔtssC-5 with S17-1/pKAS46-araPtolClux, as described previously [64].
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2.10 Virulence Assessment of a T6SS5 Mutant in Respiratory Melioidosis
Animal studies were conducted to compare the virulence of JW280 and the JW280
ΔtssC-5 mutant by IMIT infection, as described above. Groups of five animals were
euthanized at moribund end point defined as loss of righting reflex. Mice were
necropsied and lung, liver and spleen were isolated and imaged for bioluminescence in
24-well black plates. Correlations between bioluminescent signal and colony forming
units (CFU) have been previously defined [78].

2.11 Competition Studies
A gentamicin resistance cassette was amplified with flanking NotI restriction sites from
the pGSV4 vector [78] with the primers Gm cass NotI(+)
(GCGGCCGCAGATTTAAATTAATTAAGAGCTAGAATTGACATAAGCCTG) and
Gm cass NotI(-) (GAAGCGGCCGCGGCGTTGTGACAATTTACCGAACAACTC).
The Gm cassette was cloned into the pCR®-Blunt II-TOPO cloning vector (Invitrogen)
and was then cloned into the pUC19-araPtolClux vector as a NotI/NotI fragment to yield
pUC19-araPtolClux-Gm. The araPtolClux-Gm fragment was cloned into pKAS46 to
generate the pKAS46-araPtolClux-Gm and was transformed into S17-1 cells to generate
the S17-1/pKAS46-araPtolClux-Gm strain. This strain was conjugated with the B.
pseudomallei parent strain DD503, capsule polysaccharide mutant (JW270), Type 3
Secretion System translocation-deficient mutant (DD503 ΔsctUBp3) and Type 6 Secretion
System mutant (DD503 ΔtssC-5) to generate MGBP001, MGBP001 Δwcb, MGBP001
ΔsctUBp3, and MGBP001 ΔtssC-5, respectively, by allelic exchange as previously
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described [19]. Competition studies were conducted by challenging animals by IMIT
with ~104.0 CFU of a 1:1 mixture of non-luminescent B. pseudomallei DD503 plus one of
the four luminescent, gentamicin-resistant MGBP001 strains. The study was completed
at 67 hrs post infection at which point lung, liver and spleen were isolated and
homogenized. Homogenates were plated in replicate on both LB and LB-Gm plates for
bacterial enumeration and competitive index calculations.

2.12 Infection of cultured cells
J774A.1 and RAW264.7 cultured macrophages were maintained in DMEM
supplemented with 10% fetal bovine serum and grown at 37° C with 5% CO2. For
growth kinetics studies, J774A.1 macrophages were seeded at 7.5 x 104 cells per well
(100 µl) in black, solid bottom 96-well plates 1 day prior to infection. Bioluminescent B.
pseudomallei strains were grown as previously indicated. Bacterial concentrations were
estimated from OD600 readings and bacterial suspensions were diluted in PBS to desired
concentrations. Cells were infected with 5 µl of the diluted bacterial suspension.
Infections with individual strains were done in triplicate at multiplicities of infection
(MOI) ranging from 2.4 to 3.6 for the parental strain and 6.0 to 2.2 for mutant strains.
Sample wells were treated with gentamicin (20 µg/ml final concentration) 1 hr post
infection for the duration of the experiment. For siRNA knockdown studies, RAW264.7
macrophages were infected at an MOI of 10. Bioluminescence measurements were taken
every 10 minutes for a total of 14 h post infection using the IVIS Spectrum Imaging
System (Caliper Sciences).
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2.13 Cell transfection
HEK293 cells were maintained in DMEM supplemented with 10% fetal bovine serum
and grown at 37°C with 5% CO2. Cells were seeded at 6 x 104 cells per well (1 ml) on
glass coverslips in clear 24-well plates 1 day prior to infection. 600 ng of p3XFLAGbopA was transfected into the cells for 24 hrs using PEI as per manufacturer’s
instructions. For siRNA transfection, 20 µl of 0.165 µM Silencer siRNA targeting
TRAPPC8 diluted in Opti-MEM was mixed with 10 µl of Lipofectamine RNAi
Max/Opti-MEM as per manufacturer’s instruction. 30 µl of siRNA-Lipofectamine
complex was added to each well of a black, solid bottom 96-well plate, incubated for 10
min and 1 x 104 RAW264.7 macrophages suspended in 80 µL of DMEM + 10% fetal
bovine serum were added to the wells. Cells were incubated for 48 hrs at 37°C with 5%
CO2 before infection. Cells were infected as previously mentioned.

2.15 Immunofluorescent staining and confocal microscopy
For confocal microscopy, cells were fixed to coverslips with 2.5% paraformaldehyde for
15 min and washed 3 times following incubation. An anti-3XFLAG antibody diluted
1:200 in PBS was used for BopA-3XFLAG detection and cells were incubated in 17 µl of
the diluted antibody. Unbound antibody was washed 3 times with PBS and 17 µl of
Alexa Fluor 488 antibody diluted 1:4000 was used to detect the primary antibody.
Unbound antibody was washed 3 times with PBS and 17 µl of PhalloidinTetramethylrhodamine diluted 1:4000 was used for F-actin staining. Unbound antibody
was washed 3 times with PBS and glass cover slips were mounted on glass slides using
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Prolong Gold mounting media with DAPI. For vacuolar membrane staining, RAW264.7
macrophages were incubated with the lipophilic styryl dye FM4-64FX for 1 hr prior to
infection as per manufacturer’s instructions. Unbound FM4-64FX dye was washed 3
times with PBS and cell infections and vacuole isolation were conducted as previously
described. For BopA localization studies, sample plates were placed on ice to stop the
progression of infection at 2 hrs post infection. Extracellular bacteria were labeled with
mouse anti-BpMAb2 primary antibody and detection of the primary antibody was done
with an AMCA donkey anti-mouse secondary antibody. Cells were then fixed with 2.5%
paraformaldehyde for 15 minutes. Loading of anti-BpMAb2 primary antibody into the
cytoplasm of RAW264.7 cells for detection of cytoplasmic bacteria was accomplished by
selective permeabilization of the cells’ plasma membrane with the mild detergent
digitonin, at a concentration of 10 ng/mL. And detection of the primary antibody was
done with donkey anti-mouse Alexa® 547-Tetramethylrhodamine. Samples were
analyzed with the Zeiss LSM Duo-LSM5 Confocal Microscope.

2.16 Statistical analyses
Student T-test, one-way ANOVA followed by Tukey’s Multiple Comparison test, twoway ANOVA followed by the Bonferroni post-test, student T-test, Log-rank survival
analyses (Mantel-Cox test and Gehan-Breslow-Wilcoxon test) were conducted in
GraphPad Prism. Probit analysis (Finney Method, StatPlus 2009 Professional) was used
to calculate LD50 +/- standard error, which was subsequently subjected to Student T-test
analysis to investigate significant differences of LD50 values of different B. pseudomallei
strains.
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Table 1. Strains used in this study.
Strain
S17-1
S17-1/pKAS46araPtolClux
S17-1/pKAS46ΔtssC-5
DD503
DD503 ΔtssC-5
DD503 ΔsctUBp3
JW270
JW280
JW280 ΔbopA
JW280 ΔbopC
JW280 ΔbopE
JW280 ΔbapA
JW280 ΔbapC
JW280 ΔtssC-5
MGBP001
MGBP001 ΔtssC-5
MGBP001 ΔsctUBp3
MGBP001 Δwcb
MGBP002
MGBP002 ΔsctUBp3
MGBP002 ΔbopA

Description
E. coli conjugation strain, λpir
Bioluminescence allelic exchange construct
T6SS5 mutant allelic exchange construct
B. pseudomallei 1026b derivative, PmR SmR KmS
GmS, lacking AmrAB-OprA efflux pump
T6SS5 mutant
T3SS3 mutant
DD503 Δwcb capsule mutant
DD503::PtolC-luxCDABE
Bioluminescent bopA mutant
Bioluminescent bopC mutant
Bioluminescent bopE mutant
Bioluminescent bapA mutant
Bioluminescent bapC mutant
Bioluminescent T6SS5 mutant
DD503::PtolC-luxCDABE-Gm
Bioluminescent, GmR T6SS5 mutant
Bioluminescent, GmR T3SS3 mutant
Bioluminescent, GmR capsule mutant
Green Fluorescent Protein expression, JW270
Green Fluorescent Protein expression, JW270
Green Fluorescent Protein expression, JW270
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Reference
[81]
[73]
This study
[82]
This study
[19]
[60]
[73]
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

Table 2. Plasmids used in this study.
Plasmid
pBTK30
pSAM-Bt
pSAM-DYH

pEXKm5
pSAM-DKm
pKAS46
pGSV4
pCR®-Blunt IITOPO
pUC19

Vector containing Himar1 C9 transposase
Tn-seq vector for use in Bacteroides
thetaiotaomicron
pSAM_Bt with the transposase from pBTK30
inserted as a BamHI fragment to replace the
native transposase and promoter

[83]
[84]

Gene replacement vector for Burkholderia
species
Tn-seq vector
Allelic exchange vector providing KmR and SmS
in DD503 genetic background
Promoterless bioreporter vector harboring
luxCDABE operon
Topoisomerase-conjugated cloning vector

[86]

Cloning vector

[85]

This study
[87]
[78]
Invitrogen
New England
Biolabs
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CHAPTER III

TYPE 3 SECRETION SYSTEM CLUSTER 3 IS A CRITICAL VIRULENCE
DETERMINANT FOR LUNG-SPECIFIC MELIOIDOSIS

3.1 Introduction
Naturally acquired melioidosis typically involves percutaneous inoculation or
inhalation of pathogen by susceptible hosts, with many risk factors such as diabetes and
alcoholism leading to the presentation of clinical melioidosis [88]. Under exceptional
conditions, such as natural disasters, otherwise healthy individuals are also susceptible to
melioidosis [89-92], suggesting that dose and route of inoculation are key elements to
determining whether or not a healthy individual acquires disease. The ability of B.
pseudomallei to establish a lethal respiratory disease combined with its inherent
resistance to numerous classes of antibiotics and the lack of licensed vaccines against the
bacterium, highlights the importance of characterizing respiratory melioidosis for the
purposes of biodefense.
Respiratory melioidosis has been well studied in surrogate animal models for both
basic science investigations as well as therapeutic studies. B. pseudomallei has a
significant lung tropism, irrespective of the route of acquisition [88], and is able to spread
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to other tissues to cause a lethal systemic disease. Bioluminescent B. pseudomallei
strains have been generated which allow for the temporal assessment of disease
progression in individual animals using optical diagnostic imaging. In the first of such
studies, a non-lethal intranasal challenge revealed that B. pseudomallei prominently
colonizes the upper respiratory tract (URT) of mice, leading to a rapid development of
meningitis within 24 hours, likely resulting from spread to the olfactory bulbs via
olfactory nerve endings [93]. Interestingly, the symptoms of a prominent URT
colonization (rhinitis, sinusitis, tonsillitis, laryngitis, and otitis media) have not been
described as common presentations of melioidosis [94, 95], suggesting that URT
infections do not play a prominent role in humans as that observed in murine models.
Indeed, a large clinical sampling study of throat swabs revealed no carriage of B.
pseudomallei in healthy volunteers, while melioidosis patients had culturable B.
pseudomallei from the throat in 36.1% of cases [96], less than the presentation rate of
pneumonia at 50% [97]. Additionally, paired analyses of throat and sputum carriage
from the same patient demonstrated that B. pseudomallei culture from the throat is
underrepresented relative to sputum culture, suggesting that presence of B. pseudomallei
in the lung is not a direct result of a descending infection from a colonized throat [96].
These clinical trends, combined with the relatively rare presentation of meningitis at an
incident rate of 4-5% [97, 98], suggest that murine models in which B. pseudomallei is
delivered intranasally over-represent the incidence of URT disease and central nervous
system (CNS) involvement in studies of respiratory melioidosis. Significant URT
colonization was also observed by diagnostic optical imaging in a lethal intranasal murine
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model of respiratory melioidosis [73], suggesting that the URT colonization phenotype is
not specific to sub-acute disease.
The role of murine URT colonization on studies of respiratory melioidosis is
poorly understood though may have a significant impact on both basic and translational
studies. A recent study investigating an intratracheal instillation of B. pseudomallei
directly into the lungs successfully demonstrated that avoidance of initial URT
colonization could limit both CNS involvement and late stage URT colonization [99].
This finding is consistent with other studies demonstrating the mechanism by which
melioidosis-associated meningitis arises from spread to the brain from the nasal cavity
within 24 hours using both olfactory and trigeminal nerves [100]. Because intratracheal
delivery is capable of avoiding such URT and CNS involvement, an unanswered question
is what impact these cephalic disease presentations have on disease outcome of
pneumonic and systemic disease. We have developed a non-surgical approach to deliver
bacteria directly into the lung as a novel instillation strategy termed intubation-mediated
intratracheal (IMIT) inoculation, which we have validated to provide >98% efficiency in
pulmonary delivery [75], and we therefore used this highly accurate lung inoculation
approach to study the impact of lung-specific melioidosis on dissemination and disease
outcome. Additionally, we investigated whether lung-specific administration of capsular
polysaccharide and type 3 secretion mutants exhibit modified courses of disease relative
to previous characterization in other respiratory murine models. Using a combination of
optical diagnostic imaging, targeted lung-specific delivery of B. pseudomallei, and
previously characterized virulence system mutants, we demonstrate that the presence or
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absence of URT infection in murine models exhibits significant disease outcome
differences, with potential impacts on both basic and translational studies.

3.2 Results

3.2.1 Lung-specific delivery of Burkholderia pseudomallei impacts disease
progression
Opportunistic URT colonization by B. pseudomallei is associated with high rates
of meningitis in murine respiratory models [93, 101], and avoidance of bacterial
deposition on the nasal mucosa by intratracheal instillation is associated with reduced
CNS involvement [99]. We decided to investigate whether the URT colonization typical
of current respiratory melioidosis models impacts the moribund disease presentation. To
investigate this, we employed a non-surgical approach that would facilitate direct
instillation of bacteria directly into the lungs of mice with >98% efficacy [75], termed
intubation-mediated intratracheal (IMIT) delivery [74]. Albino C57BL/6J mice were used
as a model system in these studies given the myriad of transgenic tools available in the
C57BL/6J background, and the importance of coat color in optimizing detection of
bioluminescent bacterial pathogens [76]. Thus, albino C57BL/6J mice were infected
with 104 CFU of luminescent B. pseudomallei strain, JW280, using either intranasal or
IMIT delivery and monitored twice daily by optical diagnostic imaging. While challenge
with 104 CFU by both routes of inoculation resulted in moribund disease over a similar
time frame, the foci of disease in moribund animals was dramatically different (Figure 3).
As observed in our previous work with a BALB/c model [73], C57BL/6J mice infected
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intranasally developed a significant URT infection with a reduced bioluminescent signal
associated with the thoracic cavity/lung (Figure 3). Interestingly, mice infected in a lungspecific manner by IMIT developed a pulmonary infection earlier than by intranasal
delivery of the same inoculum, consistent with estimates that 10% of an intranasal
inoculum is delivered to the lung for other respiratory pathogens [102]. Importantly, the
early involvement of the lung in the IMIT model led to more severe pneumonic disease
than that observed in the intranasal model, with subsequent systemic spread not
previously observed in the intranasal model. This suggests that mice are capable of
sustaining an advanced systemic disease than previously thought possible in the
intranasal model, and therefore that URT colonization by B. pseudomallei directly
contributes to the host morbidity of the intranasal model. These data indicate that
avoiding initial deposition of bacteria in the upper respiratory mucosa represents an
important modification for studying the development of pneumonia and subsequent
systemic spread.

3.2.2 Respiratory melioidosis models exhibit similar disease kinetics
We decided to examine whether the kinetics of respiratory disease vary as a
function of the method of delivery in order to investigate whether the involvement of
different foci of infection impacts the median time to death (MTTD). Mice were infected
by either intranasal or IMIT instillation and both respiratory disease models were able to
establish an acute course of disease in C57BL/6J mice with a typical MTTD of ~4 days
(Figure 4). We observed typical dose response disease susceptibility in the intranasal
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model with a transition from 100% survivors to 100% fatality over a 32-fold dose range
(Figure 4A). Interestingly, we observed a much sharper dose transition in host
susceptibility to disease in the IMIT-infected groups, which occurred over a single tenfold dose range (Figure 4B). We calculated the LD50 of the intranasal C57BL/6J model
to be 12.1 ± 2.4x103 CFU, while the IMIT model significantly lowered the LD50 to 5.4 ±
2.0x103 CFU (P = 0.04). Thus, targeting of B. pseudomallei directly into the lungs of
mice resulted in a lowering of the LD50 and resolved host susceptibility into a more
discrete dose range transition from susceptibility to clearance of pathogen. Importantly,
the small 2.2 fold change in the LD50 and similar MTTD at equivalent doses suggest that
the ultimate course of disease takes place over a similar time frame, regardless of the
method of inoculation, but that the disease presentation is dramatically altered dependent
on whether B. pseudomallei spreads specifically from the lung, or whether initial
inoculation prominently colonizes the URT. We conclude that intranasal and IMIT
respiratory infections therefore cause very different morbidity in the host as a result of
either primarily URT or systemic endpoints, respectively.
To further investigate the role of URT colonization on disease endpoints, we
subsequently investigated the bacterial burdens of tissues isolated from moribund mice to
further characterize differences in bacterial dissemination. Tissues were necropsied from
moribund mice infected with ~LD100 doses of JW280 by either the intranasal or IMIT
routes of infection, and we compared the tissue burdens of moribund animals for the
lung, liver, spleen, BAL and blood of mice infected with (i.n.) or without (IMIT)
involvement of the URT. Consistent with the findings of Figure 3, we found that IMIT
delivery of B. pseudomallei facilities significant disease in all monitored tissues, both at
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the primary site of infection in the lung, as well as in the disseminated infection of the
liver and spleen (Figure 5). Further, we observe a >3 log CFU difference of bacterial
dissemination through the blood, indicating that moribund mice exhibit a greater degree
of septicemia in the IMIT model relative to the i.n. model. Consistent with in vivo
diagnostic imaging, bacterial tissue burden analysis reveals that B. pseudomallei
infections involving prominent URT colonization result in host morbidity associated with
reduced disease maturation in core body sites, suggesting that the host morbidity of the
i.n. model is directly influenced by the bacterial colonization of the nasal cavity.

3.2.3 Sex difference influence host susceptibility to lung-specific melioidosis
Given a recent focus in the scientific community on understanding disease
progression in both male and female model systems [103], we additionally performed
survival analyses in male albino C57BL/6J mice to investigate whether sex differences
impact susceptibility to lung-specific respiratory melioidosis. Male disease progression
closely mirrored that observed in the female models (Figure 4 and 6), where in both
cases, the 100% minimally lethal dose was observed at 104.2 CFU by IMIT, with a 91 hr
MTTD. We calculated the LD50 for lung-specific melioidosis in male mice as 1.9 ±
1.2x103 CFU, which was 2.9 fold reduced relative to the female LD50 (P = 0.25). Thus,
male mice are not significantly different in their susceptibility to respiratory melioidosis
relative to female mice in the C57BL/6J IMIT model system.
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3.2.4 Type 3 Secretion is more critical for respiratory melioidosis than capsule
We observed that URT colonization impacts disease outcome in the murine
respiratory melioidosis model, and we therefore hypothesized that URT colonization
could impact our basic understanding of the role of virulence determinants in mediating
B. pseudomallei pathogenesis. Previous murine studies demonstrated that a capsule
mutant LD50 is attenuated 101.8 fold in a respiratory melioidosis model [60], and that
T3SS3 is also required for the full virulence in an equivalent dose challenge [104]. We
therefore examined the response of albino C57BL/6J mice infected with increasing doses
of either a luminescent capsular polysaccharide mutant (JW280 Δwcb) or a T3SS3
mutant (JW280 ΔsctUBp3). We found that a capsule mutant inoculated by IMIT was not
significantly attenuated relative to the wild type strain, with a capsule mutant LD50
calculated to be 104.57 CFU (6.8 fold attenuation, P = 0.60). We observed a MTTD of 72
hrs at an ~LD100 challenge (Figure 7A), which represents a faster course of disease than
the ~LD100 dose of wild type at 91 hrs, albeit with a larger challenge dose. Thus, the
JW270 capsular polysaccharide mutant is not significantly attenuated in the lung-specific
IMIT model, contrasting with our prior findings in the i.n. model. In the IMIT model, the
T3SS3 mutant had a calculated LD50 of 106.19 CFU, which represents a significant
attenuation of 102.5 fold (P= 0.004). The course of disease of the T3SS3 was observed to
have a MTTD of 79 hr at the minimally lethal dose (Figure 7B), which like the capsule
mutant strain was faster than the wild type MTTD, albeit with a larger challenge dose.
Thus, in a lung-specific respiratory melioidosis model, T3SS3 is a critical virulence

49

determinant for B. pseudomallei in the lung, whereas the capsular polysaccharide appears
to play a more minor role.

3.2.5 Capsule and T3SS3 mutants are defective in spread from the lung
We decided to further investigate whether abrogation of URT colonization in our
lung-specific disease studies impacts the dissemination potential of the capsule and
T3SS3 mutants. We performed optical diagnostic imaging of ~LD100 infections of the
wild type strain as well as both the capsule and T3SS3 mutants to characterize bacterial
burdens at moribund disease. We found that the wild type strain is capable of
dissemination beyond the lung to colonize all sites of the body at high titer (Figure 8).
The capsule and T3SS3 mutants developed significant bacterial pneumonia yet exhibited
a spread deficiency with minimal bacterial burden outside of the lung (Figure 8). We
further characterized the dissemination defects of these mutants by enumerating bacteria
from the lung, liver and spleen, from mice infected with minimally lethal doses of each
strain. We found that while all tested strains established bacterial pneumonia of 108-109
CFU per tissue, the capsule and T3SS3 mutants exhibited significant dissemination
defects to the liver and spleen in both tissues (Figure 9). These data demonstrate that a
capsule mutant exhibits reduced fitness to disseminate from the lung, consistent with the
previously characterized role of capsular polysaccharide in mediating complement
protection [59]. Thus, a capsule mutant is capable of producing a lethal pneumonia with
a similar LD50 as wild type, yet without the wild type-ability to spread beyond this organ.
In contrast, the T3SS3 virulence determinant exhibits significantly reduced fitness in the
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lung by LD50 analysis, and this reduced fitness is also associated with a reduced
dissemination potential to the liver and spleen. Thus, both the capsule and T3SS3
mutants are spread deficient when delivered specifically to the lung, highlighting a major
difference between the current lung-specific respiratory melioidosis model versus our
previous work with i.n. models. This finding suggests that the differences in respiratory
melioidosis models, with respect to URT involvement in dissemination and endpoint,
dramatically influences our interpretation of basic science investigations of the role of B.
pseudomallei virulence determinants.

3.2.6 T3SS3 mutant exhibits reduced fitness in lung over the course of disease
We hypothesized that the reduced fitness characterized at moribund disease would
similarly be associated with a reduced fitness throughout the course of disease. We
therefore performed optical imaging of mice infected at a ~LD100 dose of JW280, JW280
Δwcb, or JW280 ΔsctUBp3 and quantified the in vivo bioluminescence until moribund
endpoints were reached. We identified an in vivo logarithmic increase in
bioluminescence of all strains in the lung, but observed that the T3SS3 mutant exhibited
reduced fitness relative to both wild type and capsule mutant strains (Figure 10). The
bioluminescence-doubling rate was calculated for all strains and we found non-significant
differences of the doubling rates of the wild type and capsule mutant strains of 9.88 and
9.24 hrs, respectively (One-way ANOVA/Tukey not significant). However, the T3SS3
mutant bioluminescence doubled at a significantly reduced rate of 13.64 hrs (P<0.001),
suggesting that the T3SS3 mutant is less fit to grow in host niches and/or is subject to
enhanced clearance by the host. This finding is consistent with our study data,
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highlighting T3SS3 as a critical virulence determinant for B. pseudomallei lung
colonization, whereas the capsular polysaccharide plays a lesser role in disease of the
lung.

3.3 Discussion
We have previously developed an optical diagnostic imaging model of intranasal
respiratory melioidosis and observed that the URT of mice infected in this manner are
subject to prominent infection [73]. URT colonization is associated with infection of the
nasal-associated lymphoid tissue (NALT) as well as infection of the olfactory bulbs/CNS
[93, 100]. As discussed above, descriptions of disease states associated with URT
infections have not been described in human melioidosis, and paired analysis of culture
sputum and throat swabs suggests that pneumonia gives rise to the presence of B.
pseudomallei at the top of the respiratory tract rather than URT carriage seeding a
primary infection which descends to the lung [96]. The over-representation of these
symptoms in mice have led us, and others, to investigate alternatives to the standard
approaches of inoculating mice with B. pseudomallei through the nares. A recently
developed intratracheal model of respiratory melioidosis succeeded in abrogating CNS
infections, suggesting that URT colonization is directly responsible for the high levels of
meningitis reported in the murine model [99, 105]. Our current studies focused on
advancing these findings by identifying whether URT infection in the mouse impacts the
overall course of disease and ask whether these impacts might influence both basic and
translational studies of respiratory melioidosis.
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Importantly, we found that inoculation of B. pseudomallei directly into the lung
dramatically altered disease outcome, where we observed significant increases in both
lung burden and septicemic spread not previously observed in intranasal inoculation
studies. Our survival analysis of intranasal and IMIT-infected mice revealed that both
routes of infection supported a disease process with very similar timing of inoculation to
moribund endpoint; however, the major difference between the models was the difference
in which host tissues supported the dominant site(s) of infection. IMIT also lowered the
LD50 relative to the i.n. model and provided an earlier development of pneumonia which
progressed to advanced systemic disease. Intranasal infection exhibits a clear bias to
nasal cavity colonization, and conversely the IMIT model achieves systemic disease at
moribund endpoints. This difference in infection site at moribund disease strongly
suggests that the causation of moribund presentation is very different in these models,
with IMIT providing systemic, general organ failure disease, while the moribund disease
of the intranasal model is very directly related to the bacterial burden in the nasal cavity.
Pathological analysis of the URT of mice infected by the i.n. route revealed significant
blockage by inflammatory cell debris in the nasal turbinates [105], thus the severe
pathology/rhinitis of the intranasal model likely promotes moribund disease. Both IMIT
and i.n. models have moribund disease symptoms which include labored breathing of
mice, and given that mice are obligate nasal breathers, we hypothesize that nasal cavity
occlusion in the intranasal model drives moribund endpoints while the labored breathing
of the IMIT model may reflect greater lung pathology, as the IMIT model supported >1
log more bacteria per lung than the i.n. model. Future studies will be required to
investigate whether the aerosol model, which would also involve the nasal mucosa as a
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primary site of infection, is similarly subjected to preferential colonization of the URT
over systemic spread.
The IMIT inoculation method we developed is distinct from other non-invasive
intratracheal instillation methods, including those used previously for B. pseudomallei
instillation [99]. IMIT inoculation is a two-step process in which mouse intubation is
followed by instillation of bacteria via a long blunt needle, and the approach facilitates an
intermediate confirmation of correct catheter placement into the trachea (rather than the
esophagus), and is therefore not prone to user error associated with unintentional misinoculation of the GI tract [106]. IMIT inoculation also benefits from being a noninvasive approach, which avoids overt deposition of bacteria into the blood stream, which
could occur as a result of surgical intratracheal inoculation.
This study incorporated use of albino C57BL/6J mice as a novel host model
system in which to study respiratory melioidosis. A vast array of murine transgenic lines
are available to the research community, the majority of which are available in the
C57BL/6J background, which have been, and will continue to be important tools in
melioidosis studies. C57BL/6 mice are commonly referred to as representing a chronic
model of melioidosis, however both in the intranasal and IMIT infection studies we found
that C57BL/6J mice develop an acute disease with a MTTD of 3-4 days. While
C57BL/6J mice do appear to have a higher resistance to respiratory melioidosis with
intranasal LD50 values 1-3 logs higher than their BALB/c counterparts [107], we
conclude that C57BL/6J mice successfully model an acute respiratory disease
presentation. We further made use of tyrosinase-negative mice, which have albino coats
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and therefore offer greater sensitivity over black-coated mice to detect bioluminescent
bacteria, which is necessary to monitor the early stages of disease progression in vivo.
We hypothesized that the improved ability to study disease maturation of
respiratory melioidosis in the absence of URT colonization might influence the role of
virulence determinants in mediating B. pseudomallei pathogenesis. Given our prior
interest in studying the role of capsular polysaccharide in mediating B. pseudomallei
dissemination from the lung, we investigated the role of a capsule mutant using IMIT
inoculation. Unlike our previous work which identified an attenuation of the Δwcb
capsule mutant of 101.8-102.3 fold in intranasal models [60, 73], we found a nonsignificant attenuation of just 6.8 fold (100.8) in the IMIT model, suggesting that the
capsular polysaccharide is not absolutely critical for the initial stages of lung
colonization. From our growing understanding of the difference between i.n. and IMIT
models, we conclude that the capsule mutant is attenuated in its ability to colonize the
nasal mucosa as the contributor to its greater attenuation in the i.n. model, and conversely
that capsular polysaccharide is not as critical for disease in the lung. More importantly,
we further characterized whether the capsule mutant is required for dissemination beyond
the lung. In our previous studies, we had found that there was no significant defect in
dissemination of the capsular polysaccharide mutant when studied at the minimally lethal
dose in the murine intranasal model [60]. This previous observation had not been
anticipated given the previous demonstration that capsular polysaccharide is required to
resist opsonization by host complement likely during dissemination through the blood
stream [59], and further that capsule is a critical virulence determinant in systemic
disease models of both the hamster and mouse with an attenuation of ~105 fold [61, 62].
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Importantly, our current studies provide a modified understanding of the role of capsular
polysaccharide in mediating dissemination beyond the lung, as we now observe that a
capsule mutant is defective in lung-specific dissemination both optical diagnostic
imaging as well as tissue burden analysis. We retrospectively interpret our previous
studies to suggest that capsular polysaccharide mutants are attenuated for colonization of
the URT mucosa, and that a capsule mutant is competent to disseminate from the URT to
the liver and spleen at wild type levels, possibly involving the NALT and lymphatic
system, as has been proposed for B. pseudomallei spread by others [93]. Only through
studying the capsule mutant in a lung-specific model system have we identified a
dissemination defect for this mutant, consistent with a dominant role for capsular
polysaccharide as a defense to innate immunity, thereby facilitating disseminated disease.
Thus, the study of the role of virulence determinants in respiratory melioidosis may give
different phenotypes dependent on whether disease is mediated by URT infection (i.n.) or
systemic disease progression (IMIT).
Type 3 Secretion has been characterized as an important B. pseudomallei
virulence determinant in hamster and murine systemic disease models as well as a murine
intranasal model system [19, 104]. B. pseudomallei possesses three T3SS clusters in its
genome [45, 46, 108], of which only cluster 3 was found to be important for mammalian
virulence, with a calculated attenuation of 102.8 fold in a systemic hamster intraperitoneal
model [19]. Given that our IMIT model revealed a reduced importance for the role of
capsule in B. pseudomallei pulmonary pathogenesis, we investigated whether T3SS3 is
an important B. pseudomallei virulence determinant in the lung, or whether it too is
required preferentially for systemic infection rather than initial lung colonization.
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Interestingly, we found that a T3SS3 translocation defective mutant was attenuated 102.5
fold, similar to the 102.8 fold attenuation reported in a systemic model. Thus, unlike the
capsule mutant, which is critical for systemic, but not respiratory, disease, T3SS3 is
required ubiquitously for both systemic and respiratory disease. It is understood that a
critical phenotype associated with the T3SS3 locus is mediating the ability of B.
pseudomallei to rapidly escape from the phagosome of professional phagocytes [38, 109].
Thus, T3SS3 mutants exhibit growth defects in intracellular niches associated with
delayed vacuolar escape, suggesting that the decreased fitness, which we have observed
for the T3SS3 mutant in the lung, is associated with reduced fitness in the intracellular
environment. Our data suggests that B. pseudomallei inhabits intracellular niches, not
only in the lung, but also in other tissues, which might explain why a similar degree of
attenuation is observed for the T3SS3 mutant in both systemic and respiratory disease
models. We are therefore interested in identifying how specific effector proteins
delivered by the T3SS3 apparatus participate in mediating vacuolar escape and increase
the fitness of B. pseudomallei in the lung.
In summary, we have demonstrated that respiratory melioidosis in the murine
model may be associated with severe upper respiratory inflammation, which directly
drives host morbidity. We have further demonstrated that simple approaches facilitating
a lung-specific disease progression allow for abrogation of URT infection, and therefore
allow mice to act as much better surrogates for human melioidosis, minimizing the role
of URT-based morbidity and CNS involvement. This approach has profound impact both
in translational studies as well as basic science investigations. In the case of the former,
full disease progression in the mouse will allow an investigation of the efficacy of pre-
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and post-exposure prophylaxis to protect against an advanced septicemic disease state.
With regards to basic science investigations, we have successfully used the IMIT model
to meet prediction of the role of capsular polysaccharide in facilitating dissemination of
B. pseudomallei from the lung, whereas our former intranasal model system did not allow
us to draw these predicted conclusions. The IMIT model has also revealed a critical role
for the T3SS3 in facilitating respiratory melioidosis.
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Figure 3. In vivo optical diagnostic imaging of respiratory melioidosis.
Female albino C57BL/6J mice were challenged with 104 CFU of luminescent B.
pseudomallei strain JW280 by either the intranasal (Top panel) or IMIT (Bottom panel)
routes of infection. Mice were imaged twice-daily beginning at 18 h post infection.
Images were uniformly adjusted to a range of 2.5x103 to 3x104 p/s/cm2/sr on a
logarithmic scale. A representative panel of images beginning 53 hr post infection is
presented for both infection routes, where the last image of each panel represents the
moribund disease endpoint.
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Figure 4. Host response to lung-specific delivery of Burkholderia pseudomallei.
Groups of 5 female albino C57BL/6J mice were challenged with increasing doses of
luminescent B. pseudomallei strain JW280 by either the intranasal (A) or IMIT (B) routes
of infection. Mice were monitored for 14 days (336 hr) for disease progression and
euthanized at the onset of moribund disease presentation. Survival curves are used to
present the dose-dependent response of the host to increasing bacterial challenges. The
MTTD was calculated for groups with ≥50% mortality, as indicated.
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Figure 5. Bacterial enumeration at moribund disease for respiratory melioidosis
models. Groups of 5 female albino C57BL/6J mice were infected by either the i.n. (105.1
CFU) or IMIT (104.6 CFU) routes of infection and euthanized at moribund disease
endpoints. Bacteria were enumerated from tissues homogenized in 1 ml PBS, from a 1
ml PBS BAL collection, or from cardiac-drawn blood. Bacterial burden was calculated
as CFU/tissue (lung, liver, and spleen) or bacteria per ml of body fluid (BAL and blood).
Significant differences between log transformed data were evaluated by 2-way ANOVA
with Bonferroni multiple comparisons (n.s., not significant; *, p<0.05; **, p<0.01; ****,
p<0.0001).
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Figure 6. Male host response to lung-specific delivery of Burkholderia pseudomallei.
Groups of 3 male albino C57BL/6J mice were challenged with increasing doses of
luminescent B. pseudomallei strain JW280 by IMIT infection. Mice were monitored for
14 days (336 hr) for disease progression and euthanized at the onset of moribund disease
presentation. Survival curves are used to present the dose-dependent response of the host
to increasing bacterial challenges. The MTTD was calculated for groups with ≥50%
mortality, as indicated.
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Figure 7. Host response to capsule and T3SS3 mutants of Burkholderia
pseudomallei. Groups of 5 female albino C57BL/6J mice were challenged by the IMIT
route of infection with increasing doses of either Δwcb capsule mutant (A) or ΔsctUBp3
T3SS3 mutant (B) in the luminescent B. pseudomallei strain JW280 background. Mice
were monitored for 14 days (336 hr) for disease progression and euthanized at the onset
of moribund disease presentation. Survival curves are used to present the dose-dependent
response of the host to increasing bacterial challenges of B. pseudomallei mutants. The
MTTD was calculated for groups with ≥50% mortality, as indicated.
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Figure 8. Detection of dissemination of Burkholderia pseudomallei mutants by
optical imaging. Groups of 5 female albino C57BL/6J mice were challenged by the
IMIT route of infection with either wild type luminescent B. pseudomallei strain JW280,
the Δwcb capsule mutant, or the ΔsctUBp3 T3SS3 mutant. Representative images of
disease endpoints are presented, with uniform image settings adjusted to a range of
2.5x103 to 3x104 p/s/cm2/sr on a logarithmic scale.

64

Figure 9. Bacterial enumeration of Burkholderia pseudomallei mutants in moribund
respiratory disease. Groups of 5 female albino C57BL/6J mice were infected with wild
type JW280 (104.2 CFU), Δwcb capsule mutant (106.0 CFU), or ΔsctUBp3 T3SS3 mutant
(106.5 CFU), and euthanized at moribund disease endpoints. Bacteria were enumerated
from tissues ex vivo by optical imaging (left Y-axis: cps/tissue) with presentation of the
estimated tissue CFU burdens based on calculated tissue-specific cps:CFU correlation
(right Y-axis: CFU/tissue est.) for lung (A), liver (B) and spleen (C). The 95% LOD was
calculated as a technical background luminescence and indicated as a dotted horizontal
line. Data points below the 95% LOD were set to the 95% LOD value. Significant
differences (1-way ANOVA with Tukey posttest) between log-transformed data sets are
indicated with an adjoining line (*, p<0.05; **, p<0.01; ***, p<0.001).
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Figure 10. Detection of pulmonary growth rates of Burkholderia pseudomallei
mutants in vivo. Groups of 5 female albino C57BL/6J mice were infected with wild type
JW280 (104.2 CFU), Δwcb capsule mutant (106.0 CFU), or ΔsctUBp3 T3SS3 mutant (106.5
CFU), and monitored by optical diagnostic imaging once to twice daily. ROIs from the
dorsally-imaged thoracic cavity were plotted as a function of infection time for each
mutant. The 95% LOD was calculated for the background luminescence of uninfected
mice and indicated as a dotted horizontal line. The calculated doubling rate of
bioluminescent signal of each strain is indicated.
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CHAPTER IV

COMPREHENSIVE IDENTIFICATION OF VIRULENCE FACTORS REQUIRED
FOR RESPIRATORY MELIOIDOSIS USING TN-SEQ MUTAGENESIS

4.1 Introduction
Respiratory melioidosis is a disease presentation of high relevance to both
naturally occurring and biodefense-related studies. Both our laboratory and others have
previously shown that the nasal cavity represents the predominant site of B. pseudomallei
colonization in intranasally inoculated mice [73, 93], whereas direct lung instillation of
bacteria can abrogate nasal cavity colonization and the associated central nervous system
involvement [78, 99]. We have further characterized that lung-specific instillation of B.
pseudomallei results in a shift of moribund endpoint from a predominant nasal cavity
infection in the intranasal model to greater bacterial proliferation in the lung and
disseminated spread [78], more closely resembling descriptions of human melioidosis.
Furthermore, the intubation-mediated intratracheal (IMIT) inoculation method facilitated
the discovery of a spread-deficiency phenotype for a capsular polysaccharide mutant
from the lung [78], which had not been discovered in mice succumbing to nasal cavity
colonization [73], and yet meets the predicted role for capsule in mediating
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protection from complement during dissemination [59]. Thus, the IMIT lung-specific
melioidosis model has begun to provide unique insights into the roles of B. pseudomallei
virulence determinants that have not been identified in other respiratory melioidosis
models.
We sought to identify additional B. pseudomallei virulence determinants by
combining our IMIT mouse model of lung-specific instillation with transposon
mutagenesis. Tn-seq is a powerful tool used to identify genes required for an organism’s
fitness in a selective environment by combining saturation mutagenesis and Next
Generation Sequencing [110]. Recent Tn-seq studies identified essential genes required
to support in vitro growth for the Burkholderia pseudomallei K96243 strain [33] and the
closely related Burkholderia thailandensis E264 strain [111, 112]. These studies
identified potential antimicrobial drug targets in key constituents of metabolic pathways,
cell structure and genes required for nucleotide and amino acid synthesis, and further
estimated that ~8% of the Burkholderia genome represent essential genes [33, 111].
Importantly, Tn-seq has not been previously used to identify B. pseudomallei genes
required to support growth in the selective pressure of mammalian host tissues. In the
present study, we investigated the potential of Tn-seq to identify virulence determinants
required by B. pseudomallei to colonize mammalian lungs in a mouse model of
respiratory melioidosis as well as to disseminate to the liver and spleen. These studies
take advantage of our IMIT respiratory melioidosis model to non-invasively target
delivery of a Tn-seq library directly into the lungs of mice to specifically identify genes
supporting pulmonary disease in the absence of potential interplay between upper and
lower respiratory tract infections.
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4.2 Results

4.2.1 Lung-specific mouse infection with the Tn-Seq insertion library
We sought to identify virulence determinants required by B. pseudomallei to
cause disease specifically in the lung, as well as subsequent disseminated spread to the
liver and spleen. Accordingly, we generated a transposon insertion library composed of
20,000 insertion mutants in the genome of the B. pseudomallei luminescent strain JW280,
a derivative of the 1026b clinical strain. To select against transposon-inactivated genes
required for lung colonization and systemic spread in vivo, we challenged groups of three
C57BL/6J albino female mice with 104.74 CFU of a transposon insertion library. This
inoculum was within 10 median lethal doses (LD50) of the JW280 strain [78], and
achieved approximately 4x coverage of the genome and 4x mutant strain representation
in the challenge inoculum. We monitored the growth rate of the mutant library by
bioluminescence starting at 19 hours post infection and observed that in the lungs, the
library pool exhibited logarithmic growth at a rate consistent with our previously
observed JW280 parent strain growth rate [78] (Figure 11A). By 66 hours post infection,
all animals had reached moribund stage, characterized by acute respiratory infection and
systemic spread (Figure 11B) and at this point all animals were euthanized and lungs,
liver and spleen were isolated. These data indicate that in vivo disease progression in
C57BL/6J mice infected with the transposon insertion library followed an acute course of
infection comparable to that of the parent B. pseudomallei strain [78].
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4.2.2 Transposon insertion sequencing and mapping
Our collaborator Dr. Deborah Yoder-Himes performed sequencing of the input
transposon insertion library to determine transposon insertion density and homogeneous
coverage of the B. pseudomallei JW280 genome. Sequencing of the input mutant library
mapped 1.1268 million reads to the B. pseudomallei 1026b genome and the mapped reads
showed that 88% percent of genes contained a transposon insertion. Approximately 8%
of the B. pseudomallei genome is estimated to represent essential genes based on in vitro
growth [33]; thus our input library coverage approached the maximum potential coverage
of 92%. As might be expected, larger genes received better coverage efficiency and
genes larger than 400 base pairs in length had over 94% coverage (Figure 12A).
We hypothesized that lung-specific delivery of the B. pseudomallei mutant library
would sustain selective pressure in the lung, which would lead to an initial loss of library
diversity and subsequent additional diversity loss following spread to the liver and
spleen. Tn-seq analyses typically investigate changes in library diversity between two
conditions using a 2-fold cutoff criteria [85, 113, 114], however, given the smaller size of
our mutant library tailored for animal infection studies, we increased the stringency of
our initial data analysis to a 3-fold cutoff. Sequencing of the output libraries showed that
at a 3-fold loss relative to the input library, transposon mutants in the lungs sustained
selective pressure leading to clearance of 1455 transposon-inactivated genes required for
lung colonization (Figure 12B). As expected, the transposon library was further reduced
in the spleen (2862 genes), suggestive of loss of library diversity both in the lung and due
to loss of genes required for disseminated spread. Surprisingly, we observed a greater
retention of diversity of the transposon library in the liver relative to the lung (765
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mutants lost in the liver compared to 1455 in the lung), suggesting that a representative
library pool reached this site prior to effects of the selective pressure exhibited in the lung
(Figure 12B). Further, the retention of library diversity in the liver relative to the lung
suggests that the liver does not exhibit as strong a selective environment as the lung, and
that the early spread to the liver is at high titer so as to avoid potential bottlenecking
effects of spread from one tissue to another. Taken together, these data suggest that B.
pseudomallei spread from the lung to the liver is a prominent dissemination path, which
occurs as an early event resulting in reduced selective pressure in the liver.

4.2.3 Burkholderia pseudomallei early hepatic dissemination
To characterize the kinetics of disseminated spread from the lung, a time course
analysis was conducted. Groups of three C57BL/6J female albino mice with 104.62 CFU,
isolated lungs, liver and spleen at 6, 12 and 24 hours post infection and enumerated
bacterial numbers from each organ. Transposon mutants were cultured from the lungs
with higher numbers than the original instilled amount by 6 hours, and grew
exponentially throughout the course of infection (Figure 13), consistent with growth
patterns observed by optical diagnostic imaging (Figure 11A). At 6 hours post infection,
transposon mutants were also present in the liver at similar numbers to those found in the
lungs (Figure 13), confirming the findings of the Tn-seq data that hepatic spread is early
and at high titer. Colonization of the spleen was detected by 12 hours post infection at or
below the limit of detection (100 CFU), where pronounced splenic colonization occurred
24 hours post infection (Figure 13). This suggests that the enhanced loss of Tn-seq
library diversity in the spleen relative to the lung is associated with later spread from the
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lung, subsequent to the effects of selective pressure in the lung. Thus, B. pseudomallei
colonize host lungs very early during infection and persist at this site through the onset of
acute respiratory disease. Similarly, bacteria can spread from the lungs at high titers to
colonize the host liver very early following infection but bacterial numbers at this site
remain constant until late in infection. This finding corroborates a unique observation
made from the Tn-seq data set, shedding new light on B. pseudomallei dissemination.

4.2.4 Identification of virulence determinants required for Burkholderia
pseudomallei colonization of host lungs
We initially focused our analysis of the Tn-seq data set on identifying virulence
determinants required by B. pseudomallei to colonize the lungs of mammalian hosts, of
which 1455 genes were required to colonize the murine lung at a 3-fold relative
abundance cutoff ratio relative to the input pool (Figure 12B). As a refined stringency to
focus our identification of key virulence determinants, we made use of a targeted analysis
of the capsular polysaccharide (CPS or CPS I [115]) biosynthetic cluster. We have
previously demonstrated that a capsule mutant was attenuated 6.8-fold relative to the
isogenic parent strain in the IMIT model, but that this level of attenuation was not
statistically significant [78]. We therefore performed a detailed analysis of the Tn-seq
lung results for the CPS I biosynthetic cluster as a benchmark genetic system, which
exhibits a marginal level of attenuation by LD50 analysis. We found that while the
majority of CPS I genes were reduced in the lung relative to the input pool, pronounced
variation in degree of response was observed across the genetic cluster (Figure 14). This
variation was suggestive of bottlenecking effects, which are possible under the
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parameters of the current study, which was designed for a biologically relevant infection
while achieving saturating library coverage. While variation was observed across the
CPS I locus, the locus itself exhibited an average 14.92-fold reduction in mutant
prevalence for the lung versus input pool. Thus to further analyze the Tn-seq lung data
set, we applied a more stringent fold-change cut off of 15-fold, reflecting the magnitude
of the average fold gene reduction of the CPS I locus. Further, we decided to identify
clusters of genes, which meet this 15-fold cutoff to mitigate the impact which
bottlenecking might have on dataset variation at the individual gene level.
A total of 548 genes underwent selective pressure in the lung at a 15-fold cutoff
relative to the input pool. These genes were heat mapped for nearest neighbor
relationship (Figure 15) to identify genetic clusters with consecutive hits of no more than
a 4-gene distance from the previous hit. The three genetic loci which provided the largest
assemblage of genes meeting these criteria included: i) CPS I (8 genes), ii) Type 6
Secretion System cluster 5 (T6SS5; 8 genes), and iii) Type 3 Secretion System cluster 3
(T3SS3; 7+5 genes) (Table 2). The T6SS5 is identified as cluster 5 by the NCBI
database [69], and this same cluster is identified as cluster 1 in Burkholderia mallei [116].
Numerous additional small genetic clusters may provide important contributions to the
fitness of B. pseudomallei in the lung. However, these data indicate that the three
prominent genetic systems contributing to B. pseudomallei lung pathogenesis are CPS I,
T3SS3 and T6SS5. Given that we have previously characterized the contribution of CPS
I and T3SS3 to respiratory melioidosis using the IMIT model [78], we decided to address
the impact of the T6SS5 system on B. pseudomallei virulence.
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Only a single gene met the 15-fold cutoff criterion in the liver (thioredoxin: -16.2fold reduced), suggesting that the liver does not offer a strong selective pressure against
B. pseudomallei relative to that of the lung. Conversely, 2255 genes met this more
stringent 15-fold cutoff criterion in the spleen, thus this criterion did not effectively
reduce the number of hits in the spleen from the 2862 hits at a 3-fold cutoff criterion.
Due to the late spread to the spleen and the large number of gene hits, we interpret that
the colonization of the spleen in this current model system is a bottle-necked event that
does not facilitate a biologically relevant data interpretation. This study therefore
focused on validating the results from the lung dataset, specifically the identification of
capsule, T3SS3 and T6SS5 as the largest genetic loci contributing to respiratory
melioidosis.

4.2.5 T6SS5 mutant is not attenuated in the IMIT model
We previously calculated the LD50 of a B. pseudomallei luminescent strain JW280
to be 103.87 CFU, a T3SS3 translocation-deficient mutant, JW280 ΔsctUBp3 to be 106.19
CFU and a CPS I operon mutant to be 104.57 [78]. While CPS I, T3SS3, and T6SS5 all
contributed to B. pseudomallei pulmonary fitness by the Tn-seq screen, single strain
challenge with a CPS mutant did not reveal an attenuation by LD50, whereas a T3SS3
mutant was significantly attenuated >200-fold [78]. We therefore challenged C57BL/6J
albino female mice with 103.95 CFU of the JW280 luminescent strain and 104.25 CFU of
the JW280 ΔtssC-5 luminescent T6SS5 mutant strain to investigate the role of T6SS5 in
respiratory melioidosis. Infection with the parent JW280 strain close to its LD50 resulted
in 67% mortality (Figure 16A), whereas infection with the luminescent T6SS5 mutant
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was 100% lethal with the 104.25 CFU dose, which is 0.52-log above the parent LD50.
Thus, the LD50 of the tssC-5 mutant is <104.25 CFU, which was not significantly
attenuated by Log-rank survival analysis relative to the parent control (Figure 16A).
Therefore, like the CPS mutant, the T6SS5 mutant is not attenuated in a single strain
respiratory model challenge. Optical diagnostic imaging was used to monitor bacterial
proliferation in the lung of lethally infected mice and by 19 hours post infection both the
parent and the T6SS5 mutant were detectable by bioluminescent imaging. However the
bioluminescent signal intensity increased at similar rates in the thoracic cavity (Figure
16B). While the T6SS5 mutant appeared to be slightly less fit than parent strain in
proliferation rate, this difference was not significant. We characterized the bacterial
tissue burden in moribund mice and found no significant difference between the T6SS5
and parent bacterial numbers in the lungs, liver and spleen (Figure 16C-D). Thus,
although our Tn-Seq analysis revealed that the T6SS5 cluster is required for the full
fitness of B. pseudomallei in the lung, single strain pulmonary challenge studies did not
support this role for T6SS5.

4.2.6 A Burkholderia pseudomallei T6SS5 mutant is attenuated in competition
studies
Given that Tn-Seq is a genome-wide competition study, and initial validation of
our Tn-Seq results using traditional LD50 estimations did not identify attenuation for the
tssC-5 mutant, we decided to investigate whether this T6SS5 mutant is attenuated by
direct competition studies. We generated a novel gentamicin-marked PtolCluxCDABE
bioluminescence reporter strain, MGBP001, which we also generated for the CPS I,
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T3SS3 and T6SS5 mutants and used these in competition studies against gentamicinsensitive, non-luminescent, DD503. Accordingly, four groups of three C57BL/6J albino
female mice were inoculated with ~104.0 B. pseudomallei at a 1:1 ratio of DD503
combined with either: i) MGBP001, ii) MGBP001 Δwcb (CPS I-), iii) MGBP001
ΔsctUBp3 (T3SS3-), or iv) MGBP001 ΔtssC-5 (T6SS5-). Infections persisted for 67 hr
(late stage disease) before lungs, liver and spleen were collected and homogenates
differentially plated on agar to identify proportions of gentamicin resistant and sensitive
strains. The MGBP001 parent strain exhibited a competition index which was not
significantly different from a ratio of 1.0 (Figure 17A), indicating that DD503 and
MGBP001 shared the same virulence potential in all tissues, suggesting that neither the
luminescence operon nor gentamicin resistance impact the virulence of B. pseudomallei.
Interestingly, all three mutant strains exhibited significantly reduced competition indices
in the lungs, liver and spleen of mice relative to the non-luminescent DD503 competition
partner (Figure 17A). Furthermore, optical diagnostic imaging of the thoracic cavity
demonstrated that the parent MGBP001 strain proliferated within the lung (Figure 17B),
consistent with the pulmonary colonization observed by the JW280 strain [78]. Imaging
was able to successfully monitor the decreased fitness of the three mutants in the lung
during the course of infection (Figure 17B), with significant differences in
bioluminescence for all but the capsule mutant by 39 hr, and for all strains by 50 hr,
indicating that optical diagnostic imaging can be used to monitor fitness defects in vivo
during competition studies. Therefore, CPS I, T3SS3, and T6SS5 are all critical
virulence determinants to support the fitness of B. pseudomallei in the lung, but
importantly, attenuation of these virulence systems by single strain challenge studies has
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only been able to identify a role for T3SS3. We propose that competition analyses,
including Tn-seq, provide a higher resolution assay by which to assess the role of B.
pseudomallei virulence determinants in the lung, and that our current Tn-seq screen
successfully identified CPS I, T3SS3 and T6SS5 as the largest genetic loci required to
facilitate respiratory melioidosis.

4.3 Discussion
In this study, we performed Tn-seq analysis to identify virulence determinants
required to cause respiratory disease in a mouse model of lung-specific melioidosis. The
primary design criteria of our screen were achieving the balance of saturating transposon
mutagenesis while also limiting the challenge dose to allow for a biologically relevant
disease progression. Previous transposon-directed insertion site sequencing and Tn-seq
libraries have been generated in the Burkholderia pseudomallei strain K96243 [33] and
its close relative Burkholderia thailandensis [111, 112] to identify essential genes
required for survival of these pathogens in vitro. Importantly, these in vitro screens
allowed for much larger library sizes to accurately identify essential genes which were
not amenable to transposon mutagenesis, which for B. pseudomallei was estimated to be
8.0% of the genome [33]. In spite of limiting library size in our study to allow for
infection studies, we achieved coverage of 88% of the genome, where the theoretical
maximum coverage is 92% based on estimates of number for essential genes. Thus, we
achieved near saturating coverage of the genome while still challenging mice with <10
LD50s of bacteria.
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An unexpected result of our Tn-seq dataset was the revelation that B.
pseudomallei is capable of reaching the liver very early in the course of infection, which
was subsequently validated by a time course infection study. These findings were
facilitated by using IMIT instillation which has been reported to efficiently deliver ~98%
of an instilled dose directly into the lung [77]. Within 6 hrs of delivery directly into the
lung by IMIT instillation, B. pseudomallei not only replicates in the lung, but also spreads
to the liver at numbers similar to that cultured from the lung. Interestingly, few genes
were critical for B. pseudomallei to maintain a presence in the liver, relative to the lung,
suggesting that the lung does not persistently seed the liver over the course of infection,
nor is the liver a source of a strong selective pressure to B. pseudomallei. Furthermore,
B. pseudomallei does not appear to replicate in the liver until late in the infection,
suggesting that the systemic fitness of the host may impact the replication potential of B.
pseudomallei in the liver, again given that Tn-seq results do not support the possibility
that the late infection increase in hepatic burden results from spread from the lung. It is
noteworthy that in other respiratory models, the liver becomes colonized at later time
points; for instance, aerosol delivery of B. pseudomallei did not result in detection of
bacteria in the liver until 3 days post infection [117]. Thus, the observation of rapid
dissemination from the lung to the liver may be a unique feature of the IMIT model, as is
the prominent moribund septicemia, which is not observed in other respiratory
melioidosis models. Future work will be required to understand the role of the liver as a
replicative niche for B. pseudomallei during respiratory melioidosis.
We developed a high specificity filter to prioritize follow-up analysis of the Tnseq results of the lung. The selection criteria was benchmarked to the capsule
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polysaccharide genetic locus which we previously demonstrated was not a critical
virulence determinant in the IMIT model of respiratory melioidosis, yet was attenuated
6.8-fold relative to parent [78]. Thus, our criteria were chosen to capture all virulence
systems, including those that may not be significantly required by LD50 analysis. Our
screen identified 548 genes, 8.7% of the genome’s predicted open reading frames
(ORFs), to be required by the bacterium for mammalian lung colonization, and of these,
32% (175 ORFs) accounted for hypothetical proteins, suggesting that additional novel
virulence systems may participate in mediating fitness within the mammalian lung.
Using cluster analysis to further prioritize the Tn-seq data set, we identified the three
dominant genetic loci contributing to respiratory melioidosis as CPS I, T3SS3 and
T6SS5. Interestingly, these systems have been previously identified as virulence systems
in systemic animal models [19, 61, 70]; however, other virulence determinants described
as important in systemic disease models did not meet our selection criteria, including the
lipopolysaccharide (LPS) biosynthetic locus which had just two genes meeting our 15fold selection criterion. Thus, virulence determinants required to support systemic
infection might not be the same as those required in the lung. Our Tn-seq analysis was
notably biased to the identification of large genetic systems, which contribute to
respiratory melioidosis, and it is therefore likely that additional genetic loci have also
been identified by this Tn-seq dataset, which will be the subject of future investigation.
Most B. pseudomallei virulence factors have been characterized primarily in
systemic infection models, including intravenous, subcutaneous, and intraperitoneal
inoculation. Indeed, the three major virulence systems targeted from our Tn-seq screen
have been well studied as major contributors to disease in hamster and mouse systemic
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intraperitoneal infection models. The capsular polysaccharide has been characterized by
several groups as providing one of the most significant contributions to the systemic
disease potential of B. pseudomallei, with capsule mutants being attenuated
approximately 5-log in these infection models [59, 62]. The significant role for capsule
in B. pseudomallei systemic disease is consistent with a demonstrated role of this
virulence factor in resisting complement opsonization of the bacteria [59], and therefore
likely a critical virulence factor for traffic between tissues, suggestive of B. pseudomallei
spread as an extracellular pathogen. Interestingly, the capsule mutant does not appear to
have a major role in the respiratory system of mice with attenuation levels of <2 log by
intranasal delivery and <1 log by IMIT instillation [60, 78]. Importantly, the T3SS3
system is known to allow for escape of B. pseudomallei from phagosomes to facilitate
rapid replication in the cytoplasm of phagocytes [38], and the ubiquitous requirement for
T3SS3 in both systemic [19] and respiratory disease models [78] suggests that the
intracellular lifestyle of B. pseudomallei is critical in all host tissues. Indeed, T3SS3 is
the only virulence system examined thus far in the IMIT instillation method that exhibits
significant attenuation by single strain challenge, suggesting that this virulence system is
one of the most critical systems for both respiratory and systemic disease. The primary
function of the T6SS5 system is not well described, though there is evidence that T6SS5
supports the intracellular lifestyle of B. pseudomallei and cell-to cell spread [118, 119].
T6SS5 system mutants are attenuated >3 log in a systemic hamster intraperitoneal model
[118] and are attenuated ~2-3 log in intranasal murine models [119, 120]. In this current
study, the role for T6SS5 in respiratory melioidosis using IMIT delivery does not appear
to be a prominent role given that we were unable to demonstrate significant attenuation in
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single strain challenge studies, which is in contrast to what has been previously reported
for the intranasal models. We have previously demonstrated that intranasal inoculation
of B. pseudomallei in mice results in a moribund disease state primarily associated with
the nasal cavity rather than the systemic disease state observed following IMIT
inoculation [78]. Thus, T6SS5 may be an important virulence factor for nasal cavity
colonization, but does not play the same critical role in the lung as seen for the T3SS3
system.
A key finding of our studies was the ability of competition studies to provide a
higher resolution identification of virulence factors in the fitness of B. pseudomallei in
the lung than single strain challenges/LD50 analyses. Similar findings have been made
for other disease model systems, where competition indexes provide a higher resolution
methodology for defining the contribution of virulence genes to a pathogen’s fitness in
animal model systems [121-123]. We had previously reported that a CPS I mutant was
not significantly attenuated by LD50 in the IMIT model [78], but presently that CPS I was
significantly attenuated by competition study in the IMIT model. Similarly, we were
unable to validate a significant attenuation for a T6SS5 mutant by single strain challenge,
but identified a significant attenuation by competition index. The Tn-seq screen itself is a
genome wide competition assay, thus our competition studies were able to successfully
recapitulate the phenotypes we identified from the Tn-seq screen results. However,
single strain challenges did not have the resolution to defined roles in respiratory
melioidosis to either capsular polysaccharide or T6SS5. These observations indicate that
competition studies have a higher resolution to ascribe roles in virulence to both CPS I
and T6SS5 in respiratory melioidosis, and thus far, T3SS3 is the sole virulence
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determinant which exhibits attenuation by LD50 in the IMIT respiratory melioidosis
model [78]. As an added feature of our competition assay, we have included a unique
optical imaging approach which is further capable of detecting significant fitness defects
in competition studies as early as 39 hrs post infection.
In summary, we provide the first phenotypic screen for B. pseudomallei virulence
factor function in the mammalian lung, and have identified the largest critical genetic
systems as CPS I, T3SS3 and T6SS5. While previously identified as virulence systems,
this study represents the first comparative study to identify these as the primary genetic
systems for respiratory melioidosis. These virulence systems therefore represent
excellent targets for the future development of therapeutics against this Tier 1 Select
Agent pathogen.
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Figure 11. In vivo disease progression of Burkholderia pseudomallei Tn-seq
transposon library. (A) In vivo growth of the B. pseudomallei transposon library in the
thoracic cavity of three C57BL/6J female albino mice infected by IMIT was monitored
twice daily with an in vivo imaging system using luminescence as a read out for bacterial
replication. Total luminescence was enumerated using a region of interest (ROI) centered
on the thoracic cavity. The dashed line indicates technical 95% limit of detection. (B)
Whole body imaging of moribund C57BL/6J mice infected with B. pseudomallei
transposon library at 66 hours post infection. The logarithmic scale bar is provided for the
standardized data presentation of 2.5x103-3x104 p/s/cm2/sr.
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Figure 12. Gene size distribution of the Burkholderia pseudomallei genome and
transposon insertion coverage. (A) Histogram of the B. pseudomallei genome (green
bars) and percentage of genes lacking transposon insertions (brown bars), both binned at
100 bp gene size intervals. (B) Tn-seq data sets were analyzed for B. pseudomallei Tnseq mutants lost by selective pressure in the lung (1455); liver (765); spleen (2862) at a 3fold reduction in relative abundance relative to the input pool. Venn diagram illustrating
mutants lost in the three tissues, with 454 genes being selected against in all three tissues.
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Figure 13. Burkholderia pseudomallei Tn-seq transposon library tissue burdens at
key sites of infection. Groups of three C57BL/6 female albino mice infected with the B.
pseudomallei Tn-seq transposon library were euthanized at 6, 12 and 24 hours post
infection. Bacterial numbers in the lungs, liver and spleen were enumerated by plate
counting and compared to bacterial numbers of moribund mice at 66 hours post infection
from the initial Tn-seq transposon library challenge. A dashed line indicates the limit of
detection of bacterial enumeration from host tissues. Tissue counts below the limit of
detection were set to the limit of detection for statistical analysis. Statistical significance
was calculated by Two-way ANOVA followed by Bonferroni post test (**, P<0.01; ***,
P<0.001; ns, not significant).
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Figure 14. Analysis of variation within capsular polysaccharide I operon genes
required for lung colonization by Tn-seq. (A) Scale representation of the capsular
polysaccharide genetic locus. (B) Variation in fold-change of capsule genes by Tn-seq
analysis of the lung data set relative to the input pool. The average fold reduction across
all capsule genes was 14.92-fold (dashed horizontal line). * denotes genes not covered in
the input library.
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Figure 15. Proximity heat map of genes required for respiratory melioidosis. The
Tn-seq lung data set was filtered for genes required by B. pseudomallei at a 15-fold
reduction cut off relative to the input pool (548 genes). Genes were sorted for their
arrangement on the two circular chromosomes of the B. pseudomallei genome, with
similar distribution density found on the larger chromosome 1 (309 genes) and smaller
chromosome 2 (239 genes). The heat map provides graphical cluster analysis of gene hits
located in close proximity (red = 1 gene distance) or distal hits (green >70 gene neighbor
distance). The three largest genetic clusters of hits separated by no more than 4 genes per
hit are indicated: capsular polysaccharide (CPS I), Type 3 Secretion System cluster 3
(T3SS3), and Type 6 Secretion System cluster 5 (T6SS5).
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Figure 16. In vivo characterization of a T6SS mutant.

(A) Survival curve of

C57BL/6 female albino mice by IMIT infected with either JW280 or JW280 ΔtssC-5. (B)
In vivo growth of B. pseudomallei strains JW280 and JW280 ΔtssC-5 infecting C57BL/6
mice, where bioluminescence was monitored twice per day and thoracic cavity total flux
(p/s) was collected from region of interest measurements. A horizontal dashed line
indicates the technical 95% limit of detection. Bacterial numbers in the lungs (C), liver
(D) and spleen (E) of C57BL/6 mice infected with either JW280 or JW280 ΔtssC-5 were
enumerated by bioluminescence measurements of ex vivo tissues, as described [77].
Statistical significance was calculated using the Student’s T test (ns: not significant).
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Figure 17. Burkholderia pseudomallei major virulence determinants are attenuated
in competition assays. (A) Competitive index of luminescent, Gm-marked parent strain
(MGBP001), capsular polysaccharide deletion mutant (MGBP001 Δwcb), T3SS3
(MGBP001 ΔsctUBp3) and T6SS5 (MGBP001 ΔtssC-5) mutants compared to Gmsensitive, non-luminescent strain, DD503. Competitive index was calculated as the
output ratio of mutant to parent divided by the input ratio of mutant to parent, having
differentially plated lung, liver and spleen homogenates on agar plates with or without
gentamicin selection. The horizontal dashed line indicates a competitive index of 1.
Statistical significance was calculated using One-way ANOVA followed by Tukey’s
Multiple Comparison Test (*, P<0.01; **, P<0.001; ***, P<0.0001). (B) In vivo growth
of MGBP001, MGBP001 Δwcb, MGBP001 ΔsctUBp3 and MGBP001 ΔtssC-5 in the lungs
was monitored twice daily using luminescence as a read out for bacterial replication, and
total flux (p/s) measurements collected from regions of interest centered on the thoracic
cavity. The horizontal dashed line indicates the 95% technical limit of detection.
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Table 3. Identification of prominent genetic loci required for pulmonary disease.
Feature ID

Fold change

Distance to
previous hit

T3SS3
bprA
bipC
bipB
bicA
bsaZ
spaP
bsaV
bsaO
BP1026B_II1643
BP1026B_II1644
BP1026B_II1645
BP1026B_II1646

Feature ID

Fold change

Distance to
previous hit

T6SS5
-70.3781
-35.0191
-15.6668
-15.2996
-56.991
-15.6396
-26.665
-82.8959
-34.0416
-59.6684
-40.3909
-33.6591

1
1
1
1
3
1
7
2
1
1
1

BP1026B_II1587
hcp-5
tssF-5
clpV-5
tagB-5
tagC-5
tssK-5
tssL-5

-83.2298
-367.19
-22.3609
-23.6294
-21.4194
-22.6434
-31.7466
-111.177

4
3
1
3
1
2
2

-36.6525
-25.4066
-36.413
-52.5586
-65.6182
-24.1121
-25.4738
-29.8059

2
3
3
2
4
2
1

Capsule
wcbF
wcbG
wcbI
wcbL
wcbM
wcbQ
wcbS
wcbT
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CHAPTER V

TYPE 3 SECRETION SYSTEM CLUSTER 3 EFFECTORS MEDIATE
BURKHOLDERIA PSEUDOMALLEI’S RAPID ESCAPE FROM HOST CELL
PHAGOSOMES

5.1 Introduction
The type 3 secretion system (T3SS) is a needle-like apparatus that translocates
effector proteins across both Gram-negative bacterial membranes into the cytoplasm of
host cells [42, 43]. T3SS translocated effectors from several Gram-negative bacteria such
as S. flexneri [124], S. enterica [125] and P. aeruginosa [126], interact with host cell
proteins to subvert the cell’s signaling pathways facilitating bacterial survival within this
intracellular niche. In its genome, B. pseudomallei encodes for 3 T3SS loci [45, 46], yet
cluster 3 (T3SS3) is the only cluster that plays an important role in the intracellular life
cycle of the bacterium in mammalian cells, specifically by promoting vacuolar escape
from endocytic vesicles [36] and overall intracellular fitness of the bacterium [38, 127].
B. pseudomallei like many other cytosolic pathogens, have evolved to rapidly
escape from endocytic vesicles by using its T3SS, following internalization into host cells
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[35]. Escape of the bacterium from the vacuolar compartment is a critical step for
intracellular survival [38] and is estimated to take place within 3 hours of internalization
[38]. However vacuole acidification occurs within 15 minutes of vacuole formation
[128], suggesting that vacuolar escape occurs earlier, as is the case with S. flexneri, which
escapes the vacuole in less than 10 minutes post internalization [129]. Once in the
cytoplasm, B. pseudomallei establishes a replicative niche by manipulating host immune
responses and signaling pathways to the bacterium’s advantage through the concerted
action of its T3SS3 translocated effectors [38]. Ultimately, B. pseudomallei lyses its host
spreading to neighboring cells and continuing the cycle of infection (Figure 2) [35].
The contributions of B. pseudomallei T3SS3 effectors to vacuolar rupture of the
bacterium are poorly understood, yet their concerted functions are critical for the
bacterium’s intracellular survival [36, 38, 48-50, 55, 56]. Putative B. pseudomallei
T3SS3 translocated effectors (Table 4) include the Burkholderia outer proteins BopA,
BopC and BopE and the Burkholderia secretion apparatus (Bsa) associated proteins
BapA, BapB and BapC [38]. Of great significance is that the T3SS3 effector BopA is
required for vacuolar rupture and rapid escape of B. pseudomallei from endocytic
vacuoles, as bopA mutants exhibit delayed vacuolar escape from phagosomes, leading to
decreased intracellular survival in RAW264.7 macrophages [36]. Other than BopA, no
role in vacuolar escape has been attributed to any other T3SS3 protein effectors. BopC
and BopE may play a role in invasion of non-phagocytic cells, as inactivation of both
effectors has been associated with a significant reduction in invasion of non-phagocytes
[48, 56]. A role of BopE in invasion of non-phagocytic cells as a guanine nucleotide
exchange factor (GEF) is consistent with the roles of its Salmonella T3SS orthologues
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SopE and SopE2, which act as GEFs for the Rho GTPases Cdc42 and Rac1, facilitating
invasion of host cells through actin network rearrangements [130]. Yet, activity of BopE
for these GTPases is much lower than that of SopE or SopE2 and notably B.
pseudomallei is only weakly invasive, suggesting that BopE may target other host
GTPases involved in distinct signaling pathways. Both BapA and BapC are secreted in
vitro in a T3SS3-dependent manner, but their effector functions during infection of host
cells remain elusive [55]. While, BopA is the only T3SS3 effector protein that appears to
directly contribute to B. pseudomallei vacuolar escape, escape of a bopA mutant is only
delayed and not completely abrogated to levels of secretion-defective mutants, strongly
suggesting that other T3SS3 effectors may also be involved in mediating the efficient
escape of B. pseudomallei from phagosomes [36, 38].
We hypothesize that additional B. pseudomallei type 3 secretion effectors may
possess distinct and complementary functions resulting in the bacterium’s rapid escape
from host cell endocytic vacuoles and full virulence in host cells. Yet, the contributions
of B. pseudomallei T3SS3 effectors to vacuolar rupture remain elusive, yet their
concerted functions are critical for the bacterium’s intracellular fitness [36, 38, 48-50, 55,
56]. Accordingly, herein we assess the growth kinetics of the B. pseudomallei T3SS3
effector mutants bopA, bopC, bopE, bapA and bapC in cultured macrophages to
investigate their impact on intracellular survival of the bacterium. We demonstrate that
the five profiled effectors facilitate full virulence of B. pseudomallei in cultured
macrophages. Finally, we investigate the role of a host cell protein with functions in
vesicular trafficking, which is potentially targeted for BopA activity, and propose a
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mechanism by which BopA interaction with this host factor results in the rapid escape of
B. pseudomallei to the cytoplasm of host cells.

5.2 Results
5.2.1 Real-time growth kinetics of bioluminescent Burkholderia pseudomallei in
cultured macrophages
We developed a high-sensitivity assay to assess the fitness of intracellular B.
pseudomallei in cultured macrophages. We used the bioluminescent B. pseudomallei
parental strain JW280, which contains a chromosomal insertion of the Photorhabdus
luminescens luxCDABE operon and exhibits constitutive light production during in vivo
and in vitro infections, allowing for the monitoring of bacterial numbers during
intracellular replication [64]. To assess the fitness of intracellular B. pseudomallei, we
infected J774A.1 cultured macrophages with JW280 and monitored the progression of
infection for ~14 hours. Macrophages were infected at multiplicities of infection (MOI)
of 5, 2, 0.5 and 0.2 in a 96-well plate format with gentamicin added to the culture media
at 1-hour post infection and maintained throughout the assay. Using in vivo optical
diagnostic imaging, we observed killing of the B. pseudomallei parental strain very early
in infection following addition of gentamicin to the culture medium, suggestive of killing
of extracellular bacteria. This early loss of bioluminescence was immediately followed
by a logarithmic growth phase, which peaked between 8.5 hours to >13 hours depending
on the MOI. Following the peak in bioluminescence, we observed a marked decrease in
bacterial bioluminescence, suggestive of macrophage cell death resulting in exposure of
bacteria to the gentamicin maintained in the culture media (Figure 18). These findings
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are consistent with previous results that showed corresponding growth patterns of nonluminescent [38, 127] and luminescent [64] B. pseudomallei parental strains.
Accordingly, we demonstrate that by using in vivo optical diagnostic imaging we can
accurately track the progression of bioluminescent B. pseudomallei infection in host cells
in real-time at very high resolution, and that this approach is amenable for use to study
the progression of infection of distinct B. pseudomallei bioluminescent strains.

5.2.2 A bioluminescent T3SS3 structural mutant exhibits a significant fitness defect
during infection of host cells
The B. pseudomallei type 3 secretion system structural mutant sctU (bsaZ) is
incapable of intracellular replication in cultured macrophages due to its impaired ability
to escape from endocytic vesicles in these cells prior to 12 hours post infection [38, 60].
Accordingly, we assessed whether the bioluminescent T3SS3 structural mutant JW280
ΔsctUBp3, was similarly defective in intracellular replication as measured by
bioluminescence. We infected J774A.1 cultured macrophages with the parental strain
JW280 or JW280 ΔsctUBp3 at an MOI of ~3 in a 96-well plate format for ~14 hours using
a gentamicin protection assay. Gentamicin was added to the culture media in each well at
1 hr post infection and maintained throughout the duration of the experiment. As
expected, the growth kinetics of the parental strain showed an initial period of bacterial
loss succeeded by a logarithmic growth-phase that peaked and quickly decreased,
suggestive of macrophage cell death resulting in exposure of bacteria to antibiotic in the
culture media. Inactivation of the structural component sctU in the T3SS3 apparatus
resulted in minimal intracellular replication of the mutant strain in J774A.1 macrophages
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prior to 12 hours post infection (Figure 19), as previously reported [38, 127]. This
reduction in intracellular replication of JW280 ΔsctUBp3 is consistent with the mutant’s
inability to escape from macrophage phagosomes, as previously described [60].
However, the sctU mutant is capable of minimal intracellular replication after 12 hours
post infection, suggestive of delayed vacuolar escape, consistent with previous
observations, which demonstrated that a sctU mutant is capable of escaping endocytic
vesicles and replicating in the cytoplasm of cultured macrophages after 12 hours post
infection [127]. Accordingly, this study confirms prior findings that demonstrate that a
functional T3SS3 apparatus is critically required for the intracellular fitness of B.
pseudomallei in cultured macrophages. Most importantly, these results validate that in
vivo optical diagnostic imaging is capable of distinguishing phenotypic differences in
intracellular bacterial viability as a non-invasive approach to study intracellular fitness of
B. pseudomallei and other intracellular pathogens.

5.2.3 T3SS3 effector proteins are required for full virulence of Burkholderia
pseudomallei in host cells
Full virulence of B. pseudomallei during infection of host cells is dependent on
the functions of the T3SS3 effector proteins [36, 48, 55, 56]. Notably, inactivation of the
T3SS3 effector gene bopA results in delayed escape of B. pseudomallei from phagosomes
of RAW264.7 macrophages, observed by transmission electron microscopy,
demonstrating that BopA is critical for the bacterium’s rapid vacuolar escape and
intracellular fitness in cultured macrophages [36]. In order to assess the contributions of
other Bop and Bap proteins to the intracellular fitness of B. pseudomallei, we infected
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J774A.1 macrophages with the bioluminescent B. pseudomallei parental strain JW280 or
the bioluminescent T3SS3 effector mutants bopA, bopC, bopE, bapA and bapC at
matched multiplicities of infection in a 96-well format. Infections were allowed to
proceed for ~14 hours, gentamicin was added to the culture media 1 hr post infection and
maintained throughout the duration of the assay. The growth kinetics of the parental
strain did not differ from the previously observed growth patterns (Figures 20 and 21).
An initial period of bacterial loss followed by a logarithmic growth phase and a marked
decrease in bacterial viability, as bacteria were exposed to gentamicin in the culture
media as a result of cell death. We monitored the growth profiles of the T3SS3 effectormutants bapA and bapC in cultured macrophages and noticed that both mutants displayed
intracellular fitness defects when compared to the parental strain (Figure 20). Bacterial
numbers for the bapA and bapC mutants only reached ~87% and ~78% of the parental
strain intracellular numbers at the peak of their growth phase, respectively (Figure 20).
In a similar manner, inactivation of bopA, bopC and bopE resulted in intracellular fitness
defects when compared to the parental strain (Figure 21). Bacterial numbers for the
bopA, bopC and bopE mutants only reached ~70%, ~89% and ~80% of the parental strain
intracellular numbers at the peak of their growth phase, respectively (Figure 21). These
results strongly suggest that all the T3SS3 effector proteins contribute to the intracellular
fitness of B. pseudomallei in cultured macrophages. Notably, the growth profiles of the
five T3SS3 effector mutants showed that inactivation of bopA, bopE or bapC resulted in
the most pronounced fitness defects (Figures 20 and 21). BopA specifically has been
shown to be involved in vacuolar escape [36], therefore this effector is important for
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intracellular fitness of B. pseudomallei by potentially directly mediating vacuolar rupture
during infection of host cells.

5.2.4 BopA exhibits delayed vacuolar escape in cultured macrophages
Previous observations through transmission electron microscopy demonstrated
that inactivation of bopA results in delayed escape of B. pseudomallei from endocytic
vesicles from cultured macrophages [36]. We showed that inactivation of bopA results in
a significant defect in intracellular survival of B. pseudomallei in cultured macrophages.
Accordingly, we aimed to validate the role of the B. pseudomallei T3SS3 effector BopA
in vacuolar escape in host cells by determining the subcellular distribution of a bopA
mutant strain early in infection. In this assay, we used the B. pseudomallei acapsular
JW270 strain, which is internalized by macrophages at comparable levels to those of he
parental strain, is capable of replicating at equivalent numbers to those of the parental
strain by ~8 hours post infection [60, 64] and has been validated for intracellular survival
assays at Biosafety Level 2 containment [131]. We infected RAW264.7 macrophages
with JW270-GFP (MGBP002), or with isogenic bopA and sctUBp3 mutants, MGBP002
ΔbopA and MGBP002 ΔsctUBp3, respectively. RAW264.7 cells were seeded on glass
coverslips for later visualization by confocal microscopy. The infection was conducted
in a 24-well format for 2 hours, gentamicin was added to the media culture at 1 hour-post
infection and maintained through the duration of the experiment. Extracellular bacteria
were labeled after infection, followed by selective permeabilization of the cells’ plasma
membrane with digitonin to label cytoplasmic bacteria and differential antibody staining
was assessed by confocal microscopy to quantify subcellular B. pseudomallei strains. We
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observed that ~40% of the parental strain MGBP002 was present in the cytoplasm of host
macrophages at 2 hours post infection (Figure 22), consistent with previous estimations,
showing that ~39% of wild type B. pseudomallei was found in the cytoplasm of
RAW264.7 macrophages at 2 hours post infection [36]. As expected, MGBP002
ΔsctUBp3 displayed a significant delay in escape when compared to the parental strain,
~20% less cytoplasmic numbers than that of the parental strain. This is consistent with
previous reports demonstrating that a T3SS3 structural mutant exhibits significant delay
in escape from RAW264.7 phagosomes [36]. Intracellular numbers of MGBP002 ΔbopA
were comparable to those observed for the MGBP002 ΔsctUBp3 structural mutant and
remained trapped at significantly higher levels relative to the parental strain in endocytic
vacuoles of RAW264.7 macrophages at 2 hours post infection (Figure 22). This is also
consistent with reduced numbers of the bopA mutant when compared to the parental
strain at later times in infected J774A.1 macrophages observed by optical diagnostic
imaging, likely due to delayed escape from endocytic vesicles (Figure 18) as previously
reported by Gong et al. [36]. Taken together these results demonstrate that the T3SS3
effector protein BopA directly contributes to the rapid escape of B. pseudomallei from
host cell endocytic vesicles.

5.2.5 BopA is associated with punctate structures in the cytoplasm of host cells
We focused on elucidating the location of BopA in HEK293 cells as inactivation
of bopA resulted in delayed vacuolar escape in host cells. A recent report of a yeast-two
hybrid screen of B. mallei virulence proteins associated with specialized secretion
systems, identified the host transport protein particle C8 (TRAPPC8) as a potential BopA
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interaction partner [132]. TRAPPC8 is the mammalian orthologue of the recently
identified Trs85 subunit of the yeast TRAPPIII complex, which has been implicated in
mediating membrane expansion in macroautophagy and the cytoplasm to vesicle pathway
[133]. Accordingly, TRAPPC8 may represent a target for BopA due to its role in
intracellular vesicular trafficking. We therefore hypothesized that BopA may localize to
distinct structures dispersed in the cytoplasm of host cells. To investigate the subcellular
location of BopA in host cells, we generated a FLAG-tagged BopA fusion protein and
transiently expressed this protein in HEK293 cells for 24 hours. Transient transfection of
the BopA-FLAG fusion protein showed that BopA was associated with punctate
structures localized to the cytoplasm of HEK293 cells (Figure 23). Accordingly,
localization of BopA to puncta in the cytoplasm of host cells supports a potential
interaction between this effector and vesicle-associated TRAPPC8, which localizes to
both vacuolar and plasma membranes [134].

5.2.6 Contribution of host transport protein particle C8 to stabilizing the
Burkholderia-containing vacuole during infection of host cells
TRAPPs are multi-subunit complexes with guanine nucleotide exchange factor
activity involved in various vesicular trafficking processes [135]. Accordingly, we
examined the role of TRAPPC8 during infection of RAW264.7 macrophages with the B.
pseudomallei JW280 parental strain as BopA may directly interact with this host factor.
We used siRNA to knockdown TRAPPC8 protein translation in RAW264.7 macrophages
or we used non-specific scrambled siRNA as a negative control. Macrophages were
treated with siRNA for 48 hours and were then infected with JW280 at an MOI of 10.
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The assay was conducted in a 96-well format and in vivo optical diagnostic imaging was
used to track the progression of infection for ~15 hours, using a gentamicin protection
assay. Growth kinetics of B. pseudomallei in macrophages treated with scrambled
siRNA exhibited the previously observed growth pattern (Figures 18 and 24), showing
initial killing of bacteria by 4 hours post infection, followed by a phase of bacterial
expansion and killing of the host cell by ~ 9 hours post infection (Figure 24).
Surprisingly, TRAPPC8 knockdown resulted in an early (~2 hours post infection)
increase in bacterial numbers in infected macrophages, followed by a sharp decrease in
numbers by 4 hours post infection, likely due to rapid loss of a viable niche for the
bacteria resulting in exposure to gentamicin in the culture media (Figure 24). These
results strongly suggest that absence of TRAPPC8 in host cells due to siRNA knockdown
results in vacuolar destabilization, releasing B. pseudomallei to the cytoplasm of the cell
to establish a replicative niche. These results also suggest that vacuolar destabilization
through TRAPPC8 function inhibition may constitute a mechanism by which BopA
promotes the rapid escape of B. pseudomallei from endocytic vesicles and ultimately
intracellular survival of the bacterium in host cells.

5.3 Discussion
We used in vivo optical diagnostic imaging to study the growth kinetics and
overall progression of B. pseudomallei infection in cultured macrophages. By using
bioluminescent B. pseudomallei to infect these host cells, we are able to monitor the
progression of disease noninvasively in a real-time, high-throughput manner and at very
high resolution. This high-throughput screen confers great advantages when
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investigating the impact of specific mutations or treatments on the fitness of diverse
bacterial strains. Further, our approach facilitates the examination of the growth kinetics
of distinct bacterial strains in different primary and cell culture models, at different
multiplicities of infection and under diverse treatments such as siRNA knockdown or
small compound libraries. Because the approach is noninvasive, observations on growth
kinetics can be made at different time points during infection, minus sample vessel
manipulation, which may reduce technical error across experimental samples. Notably,
B. pseudomallei is classified as a Tier 1 Select Agent in the United States and this
classification requires experimental use of the bacterium to be conducted under Biosafety
Level 3 containment, so minimizing manipulation of infected samples maximizes user
safety and reduces the utilization of laboratory resources such as personal protective
equipment and other consumables.
In this study, we investigated the impact of T3SS3 effector proteins on the
intracellular survival of B. pseudomallei in cultured macrophages and found that all
effector mutants exhibited defects in intracellular fitness in these cells. These results
strongly suggest that T3SS3 effectors act in concert to promote the bacterium’s
intracellular survival in host cells. Comparison of the intracellular fitness of the T3SS3
effector mutants bopA, bopC, bopE, bapA and bapC in cultured macrophages,
demonstrated that BopA, BopE and BapC play prominent roles during B. pseudomallei
infection that directly contribute to intracellular survival of the bacterium, and that other
effectors may have supportive roles to also promote intracellular fitness. Yet, further
studies are needed to validate the role of these effectors in primary cells. In addition,
finding potential host cell protein targets for BopC, BopE, BapA and BapC would further
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our understanding of B. pseudomallei pathogenesis and elucidate host proteins and
pathways exploited by the bacterium to promote its own intracellular survival.
We focused on studying the role of BopA in facilitating B. pseudomallei’s escape
from phagocytic vesicles, as bopA mutants exhibited the most profound defect in
intracellular fitness of all the profiled effectors and this defect was previously
demonstrated to be a result of delayed escape from host cell phagosomes [36]. The
trafficking particle protein C8 (TRAPPC8) was identified as a potential host cell target
for B. mallei BopA [132]. Importantly, TRAPPC8 function may facilitate vacuolar
trafficking or fusion events important for Burkholderia-containing vacuoles in host cells,
as siRNA knockdown of TRAPPC8 results in the rapid release of B. pseudomallei from
vacuoles to the cytoplasm of infected host cells. TRAPPC8, an orthologue of the Trs85
subunit of the yeast TRAPPIII complex, is required for macroautophagy and for the
cytoplasm to vacuole targeting pathway [136]. All three yeast TRAPP complexes
regulate the Rab GTPase Ypt1, an orthologue of the mammalian GTPase RAB1, through
their guanine nucleotide exchange factor domain [133] and are required for mediating
initial tethering events between vesicles and their target membrane [137]. Limited data is
available on the functions of mammalian TRAPP complexes and the attributed roles of
these complexes in mammalian trafficking pathways are based on studies of orthologous
yeast TRAPP complexes [133], although mammalian TRAPP complexes likely regulate
vesicular trafficking through RAB proteins as well.
We explored the contribution of TRAPPC8 to B. pseudomallei fitness in cultured
macrophages. Our results suggest that TRAPPC8 knockdown results in destabilization of
vesicular membranes in RAW264.7 macrophages, as evidenced by the rapid increase in
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B. pseudomallei intracellular numbers in these cells (Figure 24). Based on TRAPPIII
functions in yeast, this also suggests that disruption of TRAPPC8 function in the vacuolar
membrane of Burkholderia-containing vacuoles (BCVs) may inhibit tethering events of
vesicles to BCVs, subsequent vesicle fusion and membrane expansions events leading to
vacuolar destabilization. This is consistent with the role of the human papillomavirus L2
protein during infection of epithelial cells, which inhibits TRAPPC8 function in the
Golgi, leading to fragmentation/destabilization of this compartment [134]. We propose
that BopA binding to TRAPPC8 leads to inhibition of vesicular tethering by masking
TRAPPC8 from incoming donor vesicles, hindering interaction of the TRAPPIII complex
with the vesicle (Figure 25). Another possibility may be that BopA binding to TRAPPC8
inhibits interaction of TRAPPIII with host effector proteins required for SNARE
assembly and membrane fusion and expansion at the donor/acceptor vesicle interface
(Figure 25). Importantly, co-localization of TRAPPC8 to the Burkholderia-containing
vacuole would validate this interaction and add to the overall knowledge of mammalian
TRAPPIII function, the mechanisms involved in tethering and membrane fusion, and host
factors and pathways exploited by B. pseudomallei to promote its intracellular survival in
mammalian cells.
Overall, we demonstrated that we can monitor the progression of B. pseudomallei
infection in cultured macrophages in a real time, high-throughput manner at very high
resolution using in vivo optical diagnostic imaging and found that the T3SS3 effectors
BopA, BopE and BapC greatly contribute to B. pseudomallei’s intracellular survival in
cultured macrophages. Thus, we provide a novel approach to investigate the contribution
of both host and pathogen proteins to the establishment of the B. pseudomallei
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intracellular niche in host macrophages. Importantly, these studies will help to elucidate
vesicular trafficking patterns of the mammalian TRAPPIII complex and provide potential
host or bacterial targets for therapeutics and experimental vaccines for the prevention of
B. pseudomallei infection in humans.
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Figure 18. Growth kinetics of Burkholderia pseudomallei parental strain in J774A.1
macrophages. In vivo growth pattern of the bioluminescent B. pseudomallei parental
strain JW280 in infected J774A.1 macrophages at multiplicities of infection (MOI) of 5,
2, 0.5 and 0.2 bacteria per macrophage using a gentamicin protection assay. Growth of
B. pseudomallei was followed using in vivo imaging over a 14 hour time period using
Total Flux (total luminescence) of bacteria in photons per second. Intracellular bacterial
burden was plotted as the Total Flux of viable bacteria over time.
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Figure 19. Growth kinetics of the Burkholderia pseudomallei type 3 secretion system
cluster 3 structural mutant JW280 ΔsctUBp3 in J774A.1 macrophages. Comparison
of in vivo growth patterns of the B. pseudomallei parental strain JW280 and JW280
ΔsctUBp3 mutant strain in infected J774A.1 macrophages. Growth of B. pseudomallei was
followed using an in vivo imaging system over a 14 hour time period using Total Flux
(total luminescence) of bacteria in photons per second. Intracellular bacterial burden was
plotted as the relative percent of viable bacteria over time.
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Figure 20. Growth kinetics of the Burkholderia pseudomallei type 3 secretion system
cluster 3 effector protein mutants JW280 ΔbapA and JW280 ΔbapC in J774A.1
macrophages. Comparison of in vivo growth patterns of the B. pseudomallei parental
strain JW280 and the effector mutant strains JW280 ΔbapA and JW280 ΔbapC in
infected J774A.1 macrophages. Growth of B. pseudomallei was followed using an in
vivo imaging system over a 14 hour time period using Total Flux (total luminescence) of
bacteria in photons per second. Intracellular bacterial burden was plotted as the relative
percent of viable bacteria over time.
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Figure 21. Growth kinetics of the Burkholderia pseudomallei type 3 secretion system
cluster 3 effector protein mutants JW280 ΔbopA, JW280 ΔbopC and JW280 ΔbopE
in J774A.1 macrophages. Comparison of in vivo growth patterns of the B. pseudomallei
parental strain JW280 with the JW280 ΔbopA, JW280 ΔbopC and JW280 ΔbopE effector
mutant strains in infected J774A.1 macrophages. Growth of B. pseudomallei was
followed using an in vivo imaging system over a 14 hour time period using Total Flux
(total luminescence) of bacteria in photons per second. Intracellular bacterial burden was
plotted as the relative percent of viable bacteria over time.
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Figure 22. A BopA effector mutant exhibits delayed vacuolar escape in RAW264.7
macrophages. (A) Representative confocal images of RAW264.7 macrophages infected
with the B. pseudomallei strains MGBP002, MGBP002 ΔsctUBp3 or MGBP002 ΔbopA.
Bacteria were pseudocolored, with extracellular bacteria shown in white (blue, red and
green transposition) cytoplasmic bacteria shown in yellow (red and green transposition)
and bacteria in vacuoles shown in green. (B) Percentage of B. pseudomallei MGBP002,
MGBP002 ΔsctUBp3 and MGBP002 ΔbopA located in vacuoles of infected RAW264.7
macrophages 2 hours post infection. Statistical significance determined by 1 way
ANOVA; *** p<0.05.

114

A

BopA
B

F-actin
C

Merge
Figure 23. Ectopically expressed BopA is associated with punctate structures in the
cytoplasm of HEK293 cells. Representative confocal microscopy image of HEK293
cells transiently transfected with p3XFLAG-BopA for 24 hrs. (A) BopA-FLAG fusion
protein was detected in the cytoplasm of HEK293 cells with an anti-FLAG Alexa Fluor
488 antibody. (B) Phalloidin-TRITC binding of F-actin and (C) merged image plus
DAPI nuclear staining.
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Figure 24. TRAPPC8 knockdown promotes intracellular survival of Burkholderia
pseudomallei’s in RAW264.7 macrophages. Growth kinetics of the B. pseudomallei
JW280 parental strain in infected RAW 264.7 macrophages treated with siRNA against
TRAPPC8 (yellow line) and scrambled siRNA (pink line) for 48 hours prior to infection.
Growth of B. pseudomallei was followed using an in vivo imaging system over a 15 hour
time period using Total Flux (total luminescence) of bacteria in photons per second.
Intracellular bacterial burden was plotted as the Total Flux of bacteria over time.
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Figure 25. Model for BopA inhibition of TRAPPC8 function. Model for interaction
of the T3SS3 effector BopA and TRAPPC8 at the donor vesicle and acceptor vacuole
interface in the cytoplasm of host cells during B. pseudomallei infection. BopA binding
of TRAPPC8 may interfere with early vesicle tethering events or formation of multisubunit fusion complex formation, inhibiting vesicle expansion and leading to vacuolar
destabilization.
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Table 4. Type 3 secretion system cluster 3 putative secreted protein effectors.
Effector
Protein

Putative Effector Functional
Function
Domain/
Superfamily

Domain/Superfamily
Characteristics

BopA

T3SS3Dependent
Secretion In
Vitro
Yes

Unknown

SicP-binding
domain

Members of this family bind
the chaperone SicP, which
maintains effector stability and
ensures effector secretion.

BopC
BopE

Yes
Yes

Unknown
Guanine
nucleotide
exchange factor

Unknown
SopE-GEF
superfamily

Unknown
Members of this family
contain a C-terminal guanine
nucleotide exchange factor
domain of the Salmonella type
3 secretion system effector
SopE. This effector activates
Rho family GTP-binding
protein-dependent signaling
cascades to induce
cytoskeletal rearrangements.

BapA
BapB

Yes
Yes

Unknown
Acyl carrier
protein

Unknown
PP-binding
superfamily

Unknown
Carrier of growing fatty acid
chain bound to a
phosphopantetheine prosthetic
group covalently bound to a
serine residue during fatty acid
biosynthesis.

BapC

Unknown

Unknown

Lytic
transglycosylase domain

Members of this family
include lytic transglycosylases
in bacteria, bacteriophage
lambda and eukaryotic
lysozymes. Lytic
tranglycosylases catalyze
cleavage of β-1,4-glycosidic
bond between Nacetylmuramic acid and Nacetyl-D-glucosamine.
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CHAPTER VI

DISCUSSION AND FUTURE DIRECTIONS

In these studies, we present results that greatly contribute to our overall
knowledge of the pathogenesis of B. pseudomallei in mammalian hosts. Specifically, we
demonstrate the importance of an effective lung-specific mouse model of respiratory
melioidosis for the development of human-like melioidosis in mice. We identified the
type 3 secretion system cluster 3 as critically required for respiratory melioidosis and
other novel virulence determinants needed for B. pseudomallei lung colonization.
Further, we found that the T3SS3 effector proteins BopA, BopC, BopE, BapA and BapC
act in concert to mediate intracellular survival of B. pseudomallei in host cells. Yet, these
studies also raise additional questions that can further our understanding of host-B.
pseudomallei interactions. Accordingly, the following future directions could add to our
understanding of T3SS3 effectors to the intracellular survival of B. pseudomallei in
mammalian hosts.
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6.1 Identification and efficacy evaluation of potential Burkholderia pseudomallei
vaccine and therapeutic candidates using intubation-mediated intratracheal
instillation
Herein we show that direct delivery of B. pseudomallei to mice lungs through
tracheal intubation, leads to a course of disease with key hallmarks of human melioidosis
in mice, specifically development of respiratory melioidosis and septicaemic disease
[138]. This infection model provides a strong platform for studying the pathogenesis of
B. pseudomallei in humans, has great implications for identifying potential vaccine
and/or therapeutic candidates against B. pseudomallei infection and for evaluating the
efficacy of these potential candidates. Commonly used intranasal and aerosol inoculation
mouse models of B. pseudomallei generally result in colonization of the upper respiratory
tract by deposition of bacteria in the nasal cavity [64, 139]. This leads to
overrepresentation of neurological symptoms and incomplete disease progression with
reduced spread of the bacterium to secondary sites of infection [140] and premature
mortality in mice by suffocation [138]. Consequentially, it may be questionable to assess
therapeutic protection against suffocation end points that likely do not elicit a complete
immune response. Thus, inhalational and aerosol mouse models of melioidosis do not
model human disease correctly [139], raising challenges for identifying protective
antigens for acute and chronic melioidosis. Currently, there are no licensed vaccines
available for the prevention of melioidosis; early diagnosis and subsequent antibiotic
treatment are the only alternatives available for the management of B. pseudomallei
infection [141], thus identifying vaccine candidates against the bacterium is of pressing
concern.
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We previously established that the type 3 secretion system cluster 3 is absolutely
critical for respiratory melioidosis, strongly suggesting that the type 3 secretion apparatus
and/or its associated proteins may constitute potential vaccine and/or therapeutic targets.
However, a live attenuated mutant in the type 3 needle tip protein BipD and vaccination
with purified BipB, BipC or BipD, did not confer protection against B. pseudomallei
intraperitoneal challenge in BALB/c mice [53, 104]. We previously showed that
different routes of infection lead to altered disease outcomes [138], accordingly,
reevaluating protection and efficacy of these subunit vaccines in our lung-specific mouse
model of infection, which is associated with respiratory and septicaemic melioidosis
rather than suffocation end points, is appropriate.
Alternatively, T3SS3 structural components and associated effector proteins may
constitute potential therapeutic targets. Given that the T3SS3 is critically required for the
intracellular life cycle of the bacterium [38], it is possible that T3SS3 associated proteins
may not be accessible to humoral immune responses. By developing therapeutics that
may hinder the functions of T3SS3 key proteins or may compete for binding with target
host cell interaction partners resulting in significant bacterial attenuation, we may be able
to reduce the morbidity and mortality associated with acute melioidosis, prevent the onset
of chronic melioidosis or patient relapse.

6.2 Tn-Seq screen: A source of novel virulence determinants
We used IMIT in combination with transposon mutagenesis to identify novel
virulence factors required by B. pseudomallei to colonize the mouse lung and to spread to
the liver and spleen; all key sites of infection. Our Tn-Seq screen identified 548 genes
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required for respiratory melioidosis and of those ~512 were not associated with the
capsular polysaccharide operon, the type 3 secretion system cluster 3 or the type 6
secretion system cluster 5. The identified genes comprised 33 genetic loci, or gene
clusters with significant negative fold-changes (>15) located no more than a 4-gene
distance from adjacent hits, required for respiratory melioidosis. Numerous loci
identified possess functions related to metabolic processes during host infection, and
experienced significant negative fold-changes, suggesting that genes in these loci are
critical for bacterial survival in mammalian hosts. Specifically, genes encoding for
proteins that function in histidine, purine, amino sugars, secondary metabolites, fatty acid
and glycan biosynthesis among other cell wall components, experienced significant
negative fold-changes (>150), demonstrating a compelling requirement of these genes for
intracellular B. pseudomallei growth. Importantly, the histidine biosynthetic pathway is
only present in bacteria, archaea, fungi and plants [142], making this genetic cluster an
attractive virulence determinant for attenuation and therapeutic studies. Furthermore,
amino sugars generated in the histidine biosynthetic pathway, may also constitute
potential targets for aminoglycosides, inhibiting downstream metabolic pathways that
utilize these amino sugars and are critical for B. pseudomallei in vivo growth. Other
potential virulence determinants that may represent suitable targets for attenuation studies
include clusters involved in purine and secondary metabolite biosynthesis, loci almost
completely made up of hypothetical proteins and those that encode for surface expressed
proteins, which may be induced during various stress conditions such as early stages of
cell growth. Given the heterogeneity of host-pathogen interactions of B. pseudomallei in
the host lung, it is likely that numerous virulence systems contribute to the bacterium’s
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pathogenesis at this key site, thus validating those virulence determinants involved in
bacterial biosynthetic process that may hinder the growth of B. pseudomallei in vivo, may
confer great advantages for prevention against B. pseudomallei morbidity and mortality.

6.3 Potential role of BopE in apoptosis inhibition through activation of the RAB45
GTPase
BopE is a T3SS3 effector protein with a guanine nucleotide exchange factor
(GEF) domain [48] and is required for full virulence of B. pseudomallei in cultured
macrophages. The BopE homologues and T3SS Salmonella effectors, SopE and SopE2,
also exhibit GEF activity and target the mammalian Rho GTPases Rac1and Cdc42,
facilitating Salmonella invasion of epithelial cells [130]. BopE also exhibits GEF activity
for Rac1 and Cdc42 but to a lower extent and notably, B. pseudomallei is not an invasive
pathogen. Accordingly, we hypothesize that BopE may target other host GTPases
involved in cellular pathways, such as RAB proteins involved in vesicular trafficking,
which are exploited by numerous intracellular pathogens [143]. Although our initial
hypothesis was that BopE directly contributes to the rapid escape of B. pseudomallei
from endocytic vesicles by targeting yet known host proteins located in the Burkholderiacontaining vacuolar membrane, a recent B. mallei yeast two-hybrid screen identified the
RAB45 GTPase among other murine proteins, as a potential host cell target for BopE
[132]. RAB45 is a newly identified small GTPase of the Ras superfamily of small
GTPases [144] and its expression results in the activation of apoptosis in a human chronic
myelogenous leukemia cell line by inducing phosphorylation of the mitogen-activated
kinase p38, which leads to enhanced processing of caspase-3 and caspase-9, and
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subsequent induction of apoptosis during cellular stress [145]. The RAB45 GTPase fits
the profile of a potential BopE target, as this T3SS3 effector exhibits guanine nucleotide
exchange factor activity [48] and the potential interaction of BopE and RAB45 may
inhibit activation of the GTPase by blocking guanine nucleotide exchange, which may
result in decreased phosphorylation of p38 and ultimate inhibition of apoptosis (Figure
26). Accordingly, inhibition of programmed cell death by BopE may be a significant
benefit for B. pseudomallei as it provides the bacteria with time to establish a replicative
niche inside host cells. This hypothesis is supported by the growth kinetics of the bopE
mutant in infected macrophages, which showed a peak in intracellular numbers for this
strain at approximately 9 hours post-infection, about 2 hours before the bopA mutant
numbers reached a peak, suggesting that programmed cell death may be inhibited or
delayed in the presence of BopE. Accordingly, validating RAB45-BopE interaction and
evaluating the guanine nucleotide turnover kinetics of BopE would elucidate a potential
role for this effector to B. pseudomallei infection. Importantly, assessing the role of
RAB45 during B. pseudomallei colonization would elucidate a novel mechanism of
apoptosis inhibition by a bacterial pathogen.

6.4 BapC may modify the Burkholderia pseudomallei cell wall during infection of
host cells facilitating T3SS3 apparatus assembly
The T3SS3 effector BapC is a small 187-amino acid residue protein with
predicted amino-terminal transmembrane and lytic transglycosylase domains, and is
required for intracellular fitness of B. pseudomallei. Lytic transglycosylases are bacterial
enzymes characterized as “space-making” autolysins that cleave the β-1,4 glycosidic
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bonds between N-acetylmuramic acid and N-acetylglucosamine resulting in non-reducing
1,6-anhydro bonds in N-acetylmuramic acid peptides [146]. Lytic transglycosylases have
been shown to be involved in insertion of bacterial cell-wall spanning structures such as
pili, flagella and secretion systems; peptidoglycan biosynthesis and recycling; cell
division and maintenance of bacterial morphology [147]. These autolysins have been
implicated in the pathogenicity of several Gram-negative bacteria such as
enterohemorrhagic E. coli (EHEC) and Neisseria gonorrhoeae [148, 149] and have been
found in the T3SS and type 4 secretion system (T4SS) locus of Burkholderia cepacia,
enteropathogenic and enterohemorrhagic E. coli, S. enterica, S. flexneri, Yersinia
enterocolitica, Brucella suis, Agrobacterium tumefaciens and other bacterial pathogens
[146]. Accordingly, BapC may function as a lytic transglycosylase in the bacterial
periplasmic space during B. pseudomallei infection of host cells. Thus, we hypothesize
that BapC may modify the bacterial cell wall, creating a pore for rapid T3SS3 apparatus
assembly and passage through both bacterial membranes (Figure 26). Yet, inactivation of
bapC results in a moderate defect in B. pseudomallei survival, suggesting that other B.
pseudomallei lytic transglycosylases may complement the loss of bapC. BapC was
recently shown to be secreted in vitro in a T3SS3-dependent manner [55], yet this finding
contradicts a T3SS3 secretome screen, which did not identify BapC as a T3SS3-secreted
effector [54]. To date, the potential mechanisms of delivery of T3SS-associated lytic
transglycosylases to the periplasmic space remain relatively unknown, although some
lytic transglycosylases have been shown to encode an amino-terminal periplasmic signal
peptide sequence and are transported into the periplasmic space in a sec-dependent
manner [148, 150]. Further, the Brucella sius and A. tumefaciens T4SS-associated lytic
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transglycosylase VirB1 has been shown to transiently associate with T4SS apparatus
components, potentially providing chaperone activity for apparatus components and
traversing the bacterial inner membrane into the periplasm where it may mediate
apparatus assembly [150, 151]. Thus, it may be possible that BapC is transported into the
periplasm of B. pseudomallei through the general secretory pathway or by associating
with apparatus components permitting transport of the effector to the periplasm.
Therefore, identifying a potential periplasmic signal peptide sequence at the protein’s
amino terminal is of pressing concern. The predicted peptidoglycan pore size allows for
diffusion of globular proteins with a molecular weight of ~55 kDa or less [151] and
BapC, with a predicted 20.2 kDa molecular weight would easily diffuse through the
periplasmic space allowing the potential docking of BapC to either the inner or outer
membrane. Accordingly, identifying the subcellular distribution of BapC in the
bacterium and importantly, validating BapC transglycosylase activity with the B.
pseudomallei sacculus would provide great insight into BapC functions during infection
and its modulation of B. pseudomallei peptidoglycan dynamics in vivo.

6.5 Induction of pyroptotic and/or apoptotic cell death during Burkholderia
pseudomallei infection of host cells
The growth profile of the parental B. pseudomallei strain JW280 illustrates that
early in the course of infection, bacterial numbers are significantly reduced (Figure 18).
This decrease can be partially attributed to extracellular bacterial killing of gentamicin
added to the culture medium, but in our hands, synchronized infection of macrophages by
centrifugation leads to ~60% of bacterial inoculum internalization by 15 minutes post
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infection, which implies that infected macrophages also contribute to the decline in
bacterial numbers by killing intracellular B. pseudomallei. Yet, early killing of B.
pseudomallei by infected macrophages is not 100% effective in eradicating the
bacterium, suggesting that infected cells must resort to other methods of controlling
intracellular B. pseudomallei numbers. Cell autonomous immune responses of
macrophages against B. pseudomallei includes the induction of pyroptotic cell death
through activation of caspase-1, which takes place early during the course of infection
and seems to be dependent on bacterial strain and intracellular bacterial burden [152].
Yet B. pseudomallei can also induce apoptotic cell death in host cells [153] by
mechanisms yet unknown. We previously hypothesized that potential induction of
apoptosis may take place through activation of the MAP kinase p38 as a result of BopERAB45 interaction. Yet, activation of p38 and the outcome of this activation has been
shown to be cell type and stimulus dependent [154]. Our Tn-Seq findings showed that B.
pseudomallei colonizes and replicates in the lungs of mice as early as 6 hours post
infection, but bacterial numbers in the liver remain relatively the same by 24 hours post
infection [155], suggestive of altered immune responses associated with different cell
types. Accordingly, we hypothesize that several mammalian cell types may harbor B.
pseudomallei infection in vivo and these host cells may undergo pyroptotic or apoptotic
cell death depending on the bacterial stimuli encountered. To address this hypothesis,
first we would need to define the repertoire of mammalian cells that may harbor B.
pseudomallei infection in vivo using our lung-specific mouse model of infection and
analyze single cell suspensions from infected lungs, liver and spleen labeled with distinct
cell surface markers using flow cytometry. Once the B. pseudomallei host cell repertoire
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is defined, we have the ability to assess the role of specific caspases in inducing
pyroptotic and/or apoptotic cell death at early or late time points in infection using our
real time high throughput assay and in vivo optical diagnostic imaging. Results from
these assays will further our knowledge of the pathogenesis of B. pseudomallei in vivo,
would elucidate appropriate cell-autonomous immune responses against various B.
pseudomallei stimuli and provide potential cell targets for therapeutics against infection
with the pathogen.
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Figure 26. Model of the potential functions of T3SS3 effectors BopA, BopE and
BapC during Burkholderia pseudomallei infection of host cells. Modification of the
bacterial cell wall by BapC may facilitate passage of the T3SS3 needle through both
bacterial membranes and peptidoglycan. BopA binding to TRAPPC8 may inhibit vesicle
expansion also leading to vacuolar destabilization and the rapid escape of B.
pseudomallei from the vacuole. Potential BopE interaction with the GTPase RAB45 may
lead to inhibition of apoptotic cell death, providing B. pseudomallei the time required to
establish a replicative niche in the cytoplasm of the host cell. Other T3SS3 translocated
effector proteins likely carry out functions within the cell that promote B. pseudomallei
intracellular survival.
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findings and important scientific findings related to the NFκB signaling pathway.

TECHNICAL EXPERTISE

Select Agent and BSL-3 training

Flow cytometry

Mouse model of respiratory disease

Cell transfection

Agarose gel electrophoresis

Polyacrylamide gel electrophoresis
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Histology

Polymerase chain reaction

Immunohistochemistry

Cell culture

Antibiotic protection assays

Adenylyl cyclase assays

ELISA

In vivo imaging

Tissue sectioning

Immunohistochemistry

High-throughput screening

Confocal microscopy

Western blotting

PUBLICATIONS
Gutierrez MG, Warawa JM. Attenuation of a select agent-excluded Burkholderia
pseudomallei capsule mutant in hamsters. Acta Trop. 2016. doi:
10.1016/j.actatropica.2015.12.006.

Gutierrez MG, Yoder-Himes DR, Warawa JM. Comprehensive identification of virulence
factors required for respiratory melioidosis using Tn-seq mutagenesis. Front. Cell. Infect.
Microbiol. 2015; 5:78. doi:10.3389/fcimb.2015.00078.

Gutierrez MG, Pfeffer TL, Warawa JM. Type 3 secretion system cluster 3 is a critical
virulence determinant for lung-specific melioidosis. PLoS Neglected Tropical Diseases.
2015;9(1):e3441. doi: 10.1371/journal.pntd.0003441.

Lawrenz MB, Fodah RA, Gutierrez MG, Warawa JM. Intubation-mediated intratracheal
(IMIT) instillation: a noninvasive, lung-specific delivery system. J Vis Exp.
2014;(93):e52261. doi: 10.3791/52261.
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PRESENTATIONS
Gutierrez MG, Pfeffer TL, Warawa JM. Burkholderia pseudomallei Type III Secretion
System Cluster 3: An Exploration Into Bacterial Pathogenesis. Research!Louisville,
2013. Poster presentation

Gutierrez MG, Pfeffer TL, Warawa JM. Identification of Genetic Factors Required for
Initial Host Colonization by the Bacterium Burkholderia pseudomallei. Midwest
Microbial Pathogenesis Conference, 2013. Poster presentation

Gutierrez MG, Le J, Rodriguez-Hernandez L, McNeil K, Uriarte SM. Revamping
Neutrophil Degranulation: Inhibition Studies Using TAT-VAMP-Fusion Proteins.
Research! Louisville, 2012. Poster Presentation

Gutierrez MG, Schroeder B, Erle D. AGR2 and MUC5AC: Changes in airway epithelium
in mucous metaplasia. San Diego State University Student Research Symposium, 2011.
Oral Presentation

Gutierrez MG, Schroeder B, and Erle D. AGR2 and MUC5AC: Changes in airway
epithelium in mucous metaplasia. Annual Biomedical Research Conference for Minority
Students, 2010. Poster Presentation
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Gutierrez MG, Schroeder B, Erle D. AGR2 and MUC5AC: Changes in airway epithelium
in mucous metaplasia. Amgen Scholars Symposium, University of California, Los
Angeles, 2010. Oral Presentation

Gutierrez MG, Huxford T. Phosphate Dependency in Interfacial Metal Bridging of an
Antibody and its Antigen. San Diego State University Student Research Symposium,
2010. Oral Presentation
HONORS AND AWARDS
•

Letter of Commendation, Department of Microbiology and Immunology,
University of Louisville

2015

•

Midwest Microbial Pathogenesis Conference Travel Award Recipient

2013

•

Undergraduate Research Excellence Award, San Diego State University

2011

•

Amgen Scholars Program, University of California, San Francisco

2010

•

CSU Louis Stokes Alliance for Minority Participation Scholars Program

2010

•

NIH-Minority Biomedical Research Support/IMSD
Program Scholar

2008-2011

LEADERSHIP/COMMUNITY ENGAGEMENT
•

DuPont Manual High School Fair Judge

2014-2016

•

Louisville Regional Science and Engineering Fair Judge

2015-2016

•

Kentucky Junior Academy of Sciences Judge

2015-2016

•

Science mentor for High School student

2013-2014

•

Treasurer, Microbiology and Immunology Student Organization

2012-2013

•

Student tutor for Elementary School student

2011-2013
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